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ABSTRACT 
Neuronal cytotoxicity observed in Alzheimer’s disease (AD) is linked to the aggregation 
of β-amyloid peptide (Aβ) into toxic forms.  Increasing evidence points to oligomeric species as 
the neurotoxic species compared to fibrils; disruption or inhibition of Aβ self-assembly into 
oligomeric or fibrillar forms remains a viable therapeutic strategy to reduce Aβ neurotoxicity.  
Amyloid aggregation mitigating peptides (AAMPs) were designed based on the Aβ 
“hydrophobic core” Aβ17-20, with Cα,α-disubstituted amino acids (ααAAs) added into this core as 
disrupting agents.  The  number, distribution, and side chain functionality of ααAAs 
incorporated into the mitigator sequence was found influences the resultant aggregate 
morphology as indicated by ex-situ experiments using AFM and TEM.  For instance, AAMP-5 
incorporating the sterically hindered diisobutyl side chain to its core sequence disrupted fibril 
formation.  However, AAMP-6 with a dipropyl side chain incorporated into its core sequence 
only altered fibril morphology, forming shorter and larger sized fibrils compared to those of Aβ1-
40.  Interestingly, ααAA-AAMPs also disassembled preformed fibrils to produce either 
amorphous aggregates or protofibrillar structures, suggesting the existence of equilibrium 
between fibrils and prefibrillar structures.  Also, AAMPs aged alone did slowly aggregate to 
form spherical structures, which is inconsistent with circular dichroism spectra showing an 
unchanged random coil structure.  
Several potent mitigators of Aβ fibrillization were derived from N- or C- terminus modification 
of KLVFF with various polar groups.  The number of ααAAs and polar groups were reduced 
without affecting the overall disruptive properties of the original mitigator.
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CHAPTER 1 
GOALS, RESEARCH SYNOPSIS, AND BACKGROUND 
 
1.1 Research Goals and Aims 
 
The predominant hypothesis for the causative agents for neuronal toxicity and cell death 
observed in Alzheimer’s disease (AD) are oligomeric assemblies.1-8 One therapeutic approach is 
to target changes in the Aβ assembly process into toxic forms.  The goal of this research involves 
the design and synthesis of amyloid aggregation mitigating peptides (AAMPs) that incorporate 
ααAAs.  The use of ααAAs is of particular interest because they have been shown to induce 
extended conformations9 required for model peptides to interact and disrupt the Aβ  assembly 
process  
The specific aim of this research was to investigate the role of specific changes for one or 
two ααAAs on the Aβ assembly and disassembly process as compared to the original designs.  
The role of polar residues was also investigated with the view of reducing the overall charge of 
the peptide.  The goals were to identify which structural elements of the AAMPs are essential for 
disruption of Aβ fibrillization process or fibril dissolution. 
1.2 Research Synopsis 
Model peptides derived only from natural L-α -amino acids often yield an unordered or unstable 
secondary structure, which limits their use in potential drug candidates, biological probes, and 
functionalized-device molecules.10, 11  Thus, to increase their stability one of the ways is to 
replace the α-hydrogen of L-α-amino acid with an alkyl substituent, which results in ααAAs.  
ααAAs are known to induce extended peptide conformations, which are ideal for design 
peptides that will interact with Aβ and disrupt its assembly process.  The first aim was to 
2 
 
improve the yields of ααAAs through modification of the existing routes or development of new 
synthetic routes.  This will enable us to carry out a large-scale synthesis of ααAAs because large 
quantities are required for synthesis of peptide mitigators.  Coupling of Fmoc-ααAA-OH onto 
N-terminal resin and their N-terminal acylation were found to be difficult.  Thus, various 
coupling conditions and methods were evaluated after which a library of ααAA-containing 
AAMPs was synthesized.   
Mitigators containing ααAAs was previously shown to disrupt Aβ fibrillilization forming 
nonfibrillic assemblies that were stable after 4.5 months.  In Chapter 3 we show that the number 
and position of ααAAs in the recognition element of the original mitigator AAMP-1 (AMY-1)12 
is important in determining the effectiveness of the interaction of our AAMPs with Aβ.  Also, we 
further examine the aggregate inhibition role of each ααAA in AAMP-1 by examination of 
synthetically derived AAMP-1 analogs having ααAAs replaced by their natural amino acid 
analog (Leu for Dibg, etc).  Furthermore, a major finding is that AAMPs that disrupted fibril 
formation also led to disassembly of preformed (existing) Aβ1–40 fibrils.  
Also our two AAMPs (previously denoted as AMY-1 and AMY-2 and having a 
hydrophilic Lys tail on the C- or N-termini, respectively) mitigated Aβ1–40 fibril formation in a 
way such that ill-defined Aβ1–40 aggregates of different size were produced.  Thus, in chapter 4 
we investigate the effect of modifications of the KLVFF hydrophobic core of Aβ by replacing N- 
and C- terminal groups with various polar moieties.  Several of these terminal modifications 
were found to disrupt the formation of amyloid fibrils, and in some cases induced disassembly of 
pre-formed fibrils.  Significantly, mitigators that incorporate MiniPEG polar groups were found 
to be effective against Aβ1-40 fibrilligonesis.  In addition, we further disclose that the number of 
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polar residues (six) and ααAAs (three) in the original mitigator can be reduced without 
dramatically changing the ability to disrupt Aβ1-40 fibrillization in vitro.  
1.3 Background 
1.3.1 Protein Folding and the Evolution of Diseases 
Protein folding is crucial for sustaining cellular functions.13, 14 Amino acid sequence, mutations 
and environmental conditions such as temperature, oxidative agents and pH determine whether 
proteins misfold.  When proteins fail to fold, they are degraded by proteasome yielding unfolded 
nonfunctional proteins (non-native protein).  The unfolded proteins are thermodynamically 
unstable and tend to aggregate to regain stability.  The protein aggregates formed are deposited 
either in the body system or on organs leading to amyloidosis diseases (Table 1.1).  
Table 1.1.  Examples of protein misfolding diseases.   
 
Disease Precursor protein Deposition location 
Alzheimer’s disease β-Amyloid, Tau Brain  
Parkinson’s disease  α-synuclein  Brain  
Huntington’s disease Huntington  Brain  
Creutzfeldt-Jakob disease (mad cow) Prion protein Brain  
Amyotrophic lateral sclerosis Superoxide dismutase Brain  
Diabetes mellitus Amylin, IAPP Pancreas  
Atherosclerosis  Lipoprotein  Arteries  
Sickle cell anemia Hemoglobin  Erythrocytes  
Renal amyloidosis Fibrinogen  Kidney  
Cataract  Crystalinm  Eye  
Senile systemic amyloidosis Transthyretin  Microvasculature  
Injection-localized amyloidosis Insulin  Skin, muscles  
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Deposits localized in the regions of the brain, including the central nervous system, have 
been linked to a number of neurogenerative diseases that cause dementia.  Alzheimer’s disease 
(AD), Prion diseases, Huntington’s disease, and Parkinson’s disease,14-17 are all linked to a 
particular protein (Table 1).  The most prevalent and most studied neurodegenerative disease is 
AD. 
1.3.2 Alzheimer’s Disease 
1.3.2.1 Historical Background 
Alzheimer’s disease is the most prevalent cause of dementia in elderly humans worldwide.  The 
disease is named after the German neurologist, Alois Alzheimer (1864–1915)18-20 who studied a 
51-year-old woman who had developed memory, language and behavioral problems from 1901-
1906.  Upon her death, he examined her brain during autopsy, and noted unusual thick bundles 
of nerve fibers and the destruction of nerve cells.  He concluded that the changes that occurred in 
her brain indicated a new disease.21 It was not until 1910 when the disease was named after the 
German neurologist.  The symptoms Alois Alzheimer described are still being diagnosed in most 
patients with the disease today.22 
1.3.2.2 Alzheimer Disease Prevalence   
Alzheimer’s disease is a permanent, progressive neurodegenerative disease that gradually 
decimates memory and cognitive functions.  It is the most common cause of dementia, 
accounting for more than half of all such cases, and the sixth leading cause of death in the United 
States.  This year approximately 5.3 million people in the US have AD disease, out of which 5.1 
million people are over 65 years in age.23  New cases of the disease are expected to double by the 
year 2050.  The health care costs associated with the disease have tripled to more than $148 
billion per year, stretching Medicare and Medicaid programs.23 Worldwide, AD affects more 
5 
 
than 24 million people, with 4.6 million new cases each year.  The major risk factor for AD is 
age, with the disease prevalence increasing from 1 in 10 people for those over age of 65 to 
almost half of those over 85.24 
1.3.2.3 Etiology of AD Disease; β-Amyloid Hypothesis 
Amyloid deposits which consist of neurofibrillar tangles and senile plaques characterize 
the development of AD in the brain.25 A Large body of evidence associates the density of senile 
plaques with the severity of dementia.25, 26 Also, there is significant evidence that shows 
involvement of Tau protein, the major component of neurofibrillar tangles in etiology of AD.  
The principal component of these plaques is β−amyloid peptide (Aβ), which is derived from 
proteolytic cleavage of the transmembrane protein, amyloid precursor protein (APP), by β-and γ-
secretases.  Apart from playing a central role as a precursor to Aβ, APP have a number of 
additional functions such as autocrine and paracrine functions in growth regulation, neurite 
growth stimulation, stem cell regulation, and promotion of cell adhesion.  Mounting evidence 
implies that perturbation of some of these functions may play a part in the etiology of AD.27-30   
Cleavage of APP can occur at three different sites by  α, β, or γ secretases as shown in Figure 
1.1.  The larger extracellular segment of APP peptide is cleaved first by β- or α-secretase, 
producing membrane bound β- or α-  C-terminal fragments.  Subsequent cleavage of the β- and 
α-C-terminal fragments within the membrane by γ-secretase releases Aβ and p3 peptides 
respectively into the extracellular domain.  Two isoforms of Aβ are often produced depending on 
γ-secretase cleavage site; Aβ1-40 (between 40 and 41) and Aβ1-42 (between 42 and 43).  The other 
by-product of γ-cleavage is the cytoplasmic polypeptide, AICD that so far has not been 
investigated for any role in the etiology of AD.  
 
 Figure 1.1.  Cleavage of APP molecule by aspartyl proteases
It is widely accepted that A
mechanism of neurotoxicity has not been fully established.
animal, and in vitro studies have supported the central role of A
instance, synthetic Aβ has been shown 
experiments.35-38 Also, there was an increase in tau hyper
were injected with synthetic Aβ, leading to formation of tangles.
until it aggregates to form an array of oligomeric and fibrillar structures.  Therefore identifying 
and characterizing the toxic Aβ
developed.  
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β plays a central role in the etiology of A
13, 20, 31-33
 Several human, transgenic 
β in etiology of AD
to be toxic to neurons both in vivo
phosphorylation when transgenic mice 
39, 40
 Monomeric A
 species is crucial so that compounds that target them can be 
 
D, although the 
.  For 
34
 and in vitro 
β is nontoxic 
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1.3.2.4 Aβ Αggregation  
The peptide Aβ is a normal, soluble component of human plasma and cerebrospinal 
fluid.41, 42 It is toxic only after it undergoes aggregation and/or conformation change to higher 
ordered species such as oligomers or fibrils.35, 43-45 The most common isoforms of Aβ are Aβ40 
and Aβ42, which differ only by the length of the C terminus.  The concentration of secreted 
Aβ42 is about 10% that of Aβ40, and yet the predominant component of senile plaques is 
Aβ42.46-49 Biochemical studies have shown that Aβ42 aggregates and forms fibrils more quickly 
than Aβ40.50-52 Monomers, dimers, trimers, and tetramers, in rapid equilibrium are the major 
early aggregation products of Aβ40.3, 5, 53 In contrast, Aβ42 preferentially form pentamer and 
hexamer units (paranuclei) that assemble further to form beaded superstructures, similar to early 
protofibrils.54 This could explain why assemblies formed by Aβ42 are more toxic as compared 
to those formed by Aβ40 during early stages of oligomerization.  Also, over expression of the 
two isoforms in transgenic mice demonstrated that Aβ42 is involved in amyloid pathology.55 
In vitro, synthetic Aβ has been shown to aggregate via various intermediate species 
including soluble oligomers, protofibrils, and insoluble fibrils.56  This process depends on a 
number of aggregation conditions, such as acidic pH, metal ions, osmolytes, and interaction with 
lipid membranes.57-61  The mechanism of Aβ aggregation into the toxic species has been shown 
to proceed via two distinct pathways.  In the presence of preformed fibrils or plaques, Aβ 
aggregates by consecutive association onto the ends of existing fibrils.62, 63 However, in the 
absence of seeding, Aβ monomers aggregate into fibrils by a two step-polymerization process; 
nucleation and elongation, in which nucleation is the rate determining step.7, 43, 64-66 The 
nucleation phase is a result of an energy barrier that must be overcome in order for Aβ monomers 
 to fold into nuclei.67 Once the nuclei have been generated, rapid elongation of fibrils occurs in 
the linear phase.   
Figure 1.2.  The nucleation process of fibrillogenesis
 
Computer simulation experiments have also shown that 
step process that is reliant on the degree of hydrophobicity
interactions between hydrophobic residues monomers coalesce quickly into disord
oligomers.  The disordered assemblies reorganize (conformational change) slowly through 
formation of interchain hydrogen bonds into ordered oligomers rich in 
conformational change, the hydrophobic residues buried inside the oligo
interaction with cellular components such as membranes.  This could explain the toxic nature of 
oligomers.  When hydrophobicity is inadequate to drive coalescence to disordered oligomers, 
peptides form ordered oligomers directly as a re
and concentration are other factors that affect formation of disordered assemblies.
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monomeric Aβ peptides undergo a two
.  In the first step, due to strong 
β-sheets
mers are exposed to 
sult interchain of hydrogen bonds.  Temperature 
 
-
ered 
.  Because of 
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The morphology of amyloid fibrils formed by various amyloidal proteins such as Aβ, α-
synuclei, amylin, and β-microglobulin has been studied using atomic force microscopy (AFM).66  
A hierarchical assembly model (HAM) has been proposed to describe the assembly process of 
amyloid proteins into fibrils.68, 69 The HAM model predicts that a monomeric amyloid protein 
aggregates via a nucleated polymerization mechanism into protofilaments, which elongate by 
addition of monomers at the ends of protofilaments.  Two or three protofilaments can associate 
to form protofibrils that intertwine to form fibrils.  In general, the HAM model predicts that 
fibrils and protofibrils will exhibit clumping, periodicity, variations in height, and branching.    
1.3.2.5  Neurotoxicity of Aβ  
The original “amyloid cascade” hypothesis linked the deposition of fibrillar Aβ in the 
brain to neuronal cell death.  1, 70-72 However, some key observations including poor correlation 
between deposition of plaques and severity of dementia contradicts this hypothesis.  Therefore, 
the amyloid cascade hypothesis was amended to include soluble oligomeric assemblies rather 
than fibrils as the main neurotoxic species.  This was because a number of studies have shown a 
stronger correlation between soluble oligomers and severity of AD than fibrils.  In addition, 
transgenic mice APP models exhibited memory and synaptic dysfunction long before plaques 
(fibrils) were detected.73-75  
The solubility and small sizes of oligomeric species is believed to be a crucial factor as to 
why oligomers are more toxic than fibrils.  In addition, the higher surface area to volume ratio 
exhibited by oligomers as compared to fibrils ensures maximum interaction with neurons, hence 
increased neurotoxicity.  The interaction between oligomers and neurons has been shown to 
occur by either insertion of oligomers between membrane layers to generate cytotoxic pores, or 
binding of oligomers specifically to neuron surfaces as ligands.76, 77 
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Oligomeric assemblies consist of curvilinear structures (protofibrils) that normally appear 
as beaded strings and globular particles with heights ranging from 2-5 nm.  Protofibrils were 
identified several years ago as intermediates that form during the Aβ assembly process into 
fibrils,37, 78 and protofibrils have been shown to kill neurons.1, 79 More recently, globular 
oligomers were renamed amyloid–β-derived diffusible ligands (ADDLs) to emphasize their 
globular nature but also to differentiate from the general “oligomers” that include nontoxic 
assemblies.  The ADDLs were initially discovered from aging Aβ1-42 in the presence of clusterin 
when no fibrils were formed and yet a dramatic increase in toxicity was observed.6, 80 Only 
nanomolar concentrations of Aβ1-42 are needed to make stable ADDLs that have units ranging 
from trimers to 24-mers.  The hypothesis that ADDLs plays a crucial role in AD is gaining 
momentum.  This is specifically because ADDLs bind neuronal receptors inducing synaptic 
dysfunction rather than the neuronal death caused by fibrils and plaques.  Other general 
consequences caused by Aβ aggregates include alteration of the physiological properties of 
membranes, membrane-mediated triggering of neuronal cell death, lipid peroxidation, and 
calcium-permeable membrane ion-channels.  Although increasing evidence points to oligomeric 
species as the more toxic species, a general strategy to prevent AD may be to interrupt the 
assembly of Aβ into these toxic forms. 
1.3.2.6 Strategies for Designing Molecules That Target Aβ 
Considerable research effort has focused on discovery of inhibitor compounds that block 
the toxicity of Aβ, by targeting a specific step involved in Aβ aggregation.81-83 Given the 
hypothesis that aggregation intermediates are responsible for Aβ toxicity, such compounds could 
theoretically prevent all aggregation, or alternatively cause further association of toxic oligomers 
into larger nontoxic aggregates. 
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Several approaches are under development against production of Aβ and related 
aggregates.  These include inhibition of proteases involved in cleavage of Aβ from APP,84-
88antibody therapy through passive immunizations using anti-Aβ antibodies,89-92 non-antibody 
based natural mechanism,93-95 small molecules,96-100 and peptides.100  Peptide-based Aβ 
interacting molecules are the focus of this dissertation.  Interest in peptides has intensified 
because they are generally more potent, and show higher specificity and fewer toxicology 
problems than smaller molecules.  Peptide-based drugs approved by the FDA include natural 
peptides, such as insulin, vancomycin, oxytocin, and cyclosporine and synthetically produced 
ones, such as Fuzeon (enfuvirtide) and Integrilin (eptifibatide).  The development of new non-
oral drug delivery methods such as subcutaneous  and  intranasal implants has increased the 
interest in peptide-based drugs. 
One approach is to exploit the self-recognition features of Aβ to generate compounds that 
can interact specifically with Aβ.101, 102 Tjenberg et al. identified residues 16-20 (KLVFF) to be 
essential for fibril formation.62, 103 Pentapeptide KLVFF was also found to be the minimum 
sequence required to bind Aβ40/42.102, 104 Several groups have developed amyloid aggregation 
mitigating peptides (AAMPs) based on the KLVFF motif that alter aggregation kinetics or 
aggregate morphologies of Aβ.  The common design of these AAMPs is to use the KLVFF core 
as a recognition element, since the initial assembly of Aβ into oligomeric assemblies is 
controlled by hydrophobic interactions through side chains.  Several modifications of the 
KLVFF motif reported include amino acid substitutions with regular amino acids, α-carbon 
modification of some amino acid residues, KLVFF terminal modification using polar groups, 
peptide backbone atoms modification with ester, isostructural double bond, N-methylation, 
peptide cyclization with cystines, and insertion of D-amino acids.105-107  The design strategy 
 employed both α-carbon and C- 
potent mitigators of Aβ fibrillization.
1.3.2.7 Structures of Aβ Assemblies
Figure 1.3.  Structural model of the protofilament in A
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neurotoxicity.  The structural characterization of oligomers has not been reported because of 
their noncrystaline nature.  Unlike oligomers, fibrils have a well
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through solid-state NMR studies has shown that Aβ fibrils favor C2 symmetry.108, 109 The 
symmetry is stabilized by hydrophobic interactions between the two parallel sheets adopted by 
single Aβ molecules and between two separate Aβ molecules.  A salt bridge between Asp23 and 
Lys28 also contributes to the stability of the fibril structure.110 Fibrils formed by longer forms of 
Aβ (Aβ1-40 and Aβ10-35) were more likely to consist of parallel β-sheets as compared to 
antiparallel β-sheets for fibrils formed by shorter peptide segments, Aβ16-22, Aβ11-25, and Aβ34-
42.
110
  
1.4 Conclusion 
Alzheimer’s disease AD is a neurodegenerative disease that affects nearly 5.3 million people in 
the US and new cases of the disease are expected to double by the year 2050.  There is still no 
cure for the disease, but drugs in the market act only to slow down progression of the disease.  
Current approaches to the development of possible therapeutic involve targeting of secretases 
responsible for secretion of Aβ as well as the toxic structures formed during Aβ assembly into 
fibrils.  Oligomeric and protofibrillar assemblies have been shown to be more toxic to neurons 
than fibrils.  Unlike fibrils, no structural data has been reported for oligomeric structures.  
Structural determination of oligomers is urgently needed in order to find ways of stabilizing or 
disrupting their formation.  Peptide-based drugs offer great potential because of their specificity 
and limited side effects as compared to small molecules, especially with the development of non-
oral methods of drug delivery.  The lethality of AD and the excessive financial and social cost 
associated with it require that all possible leads be pursued. 
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CHAPTER 2 
SYNTHESIS OF ALPHA, ALPHA-DISUBSTITUTED AMINO ACIDS (ααAAS) AND 
THEN INCORPORATION INTO SHORT PEPTIDES 
2.1 Introduction 
Peptide-protein or protein-protein interactions play an important role in many cellular processes, 
hence what is an increasingly popular source for the design of inhibitors.  One approach involves 
designing short model inhibitor peptides that will interact with specific residues in the target 
molecule.1 Such model peptides allow elucidation of the roles of the target molecules in cellular 
function as potential targets for development of new therapeutic agents.  Tjernberg et al. 
identified residues KLVFF as critical for self recognition and fibril formation.1 Effective 
mitigators of Aβ assembly are reported to incorporate this region in their core sequence.  For a 
mitigator to interact with Aβ, it has to adopt an extended conformation similar to Aβ.  Cα,α-
disubstituted glycine residues (ααAAs) have been shown to promote helical or extended 
conformation depending on substituent’s at the α-carbon.  Thus, short peptides incorporating one 
or more ααAAs adopt an extended conformation with two faces where one face containing 
ααAAs blocks the necessary hydrogen bonds required for β-sheet extension and the other face is 
available for interaction with Aβ.  In addition, ααAAs increase the stability of ααAAs-
containing peptides from proteolytic degradation, enhancing their potential as therapeutic agents.  
This dissertation will focus mainly on synthesis of the ααAAs dibenzylglycine (Dbg), 
dipropylglycine (Dpg) and diisobutylglycine (Dibg) and their incorporation into model peptides 
as possible mitigators of Aβ assembly.  We hypothesize that these ααAAs that have larger side 
chains than methyl groups when incorporated into a model peptide will induce extended peptide 
conformations.  Thus, peptides containing ααAAs would have strong affinity for β-sheet 
assemblies and block one punative face from hydrogen bonding with another β-sheet moiety.  
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The inhibitor peptides consist of hydrophobic core of Aβ16-20 where ααAAs are substituted 
into hydrophobic core of Aβ at key positions. 
2.2 Experimental Section 
2.2.1. Materials and Instruments 
2.2.1.1 Materials 
Fmoc-protected amino acids and Fmoc-PAL-PEG-PS support (initial loading 0.16-0.22 
mmol/g) were purchased from Applied Biosytems (Foster, CA), Novabiochem (Darmstadt, 
Germany), or Peptide international (Louisville, KE).  N-[(dimethyamino)-1H-1, 2, 3-triazolo[4, 
5-b]pyridino-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU),  
7-azabenzotriazol-1-yloxy-tris-(pyrrolidino) phosphonium hexafluorophosphate (PyAOP), N-
hydroxybenzotriazole (HOBt),  1-Hydroxy-7-Azabenzotriazole (HOAt), O-Benzotriazole-
N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU), and  O-(Benzotriazol-1-yl)-
N,N,N',N'-tetramethyluronium tetrafluoroborate were obtained from Applied Biosystems (Foster 
CA) or  GL Biochem Ltd (Shanghai, China). N,N'-dicyclohexylcarbodiimide (DCC), N,N'-
diisopropylcarbodiimide (DIC), bis(2-oxo-3-oxazolidinyl)phosphonic chloride (BOP-Cl), 
triisopropylsilane (TIPS), trifluoroacetic acis (TFA), benzyl bromide, ethylnitroacetate,  
Diisopropylethylamine (redistilled), liquefied phenol and solvents (drum) were purchased from 
Sigma-Aldrich (Milwaukee, WI). Diisopropylethylamine (DIEA), piperidine (4-
methypiperidine) and collidine were obtained from Fisher Scientific. TLC plates and silica gel 
were purchased from sorbent technologies 
2.2.1.2 Instruments 
• GC/MS: Varian Saturn 2200 GC/MS 
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• Mass Spectrometry: Bruker ProFLEX III MALDI-TOF mass spectrometer and Agilent 
6210 time-of-flight MS 
• 2.2.1.2.3 Microwave: MARS System with XP-1500 PlusT vessels, the ESP-1500 Plus 
and RTP-300 
Table 2.1 microwave-coupling conditions 
 
• Peptide Synthesizer: MilliGen 9050 PepSynthesizer 
• NMR: Bruker DPX-250 and Bruker AV-400 
 
•  Amino Acid Analysis: Dionex AAA-Direct instrumentation 
• Circular dichroism (CD): Aviv Circular Dicroism Spectrometer Model 62DS  
• HPLC: Waters 
Software: Empower 
Controller: Waters 600E (multisolvent delivery system) 
Pump:  Waters 625  
Detector: Waters 486 UV detector set at 220 nm 
Columns:  Waters Delta-Pak C4 (15µm, 100 Å), 8×100 mm for analytical HPLC  
   Waters Delta-Pak C4 (15µm, 100 Å), 25×10 mm for preparative HPLC 
Buffer A: H2O, 0.1 % TFA (v/v) 
Buffer B: ACN, 0.1 % TFA (v/v 
Amino acid Power (watts) Coupling time  Hold temperature 
ααAAs 400 10 95 
Symmetrical anhydride 400 20 75 
Natural amino acid 400 5 75 
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Table 2.2. Standard method for analytical HPLC 
Time (min) Buffer A (%) Buffer B (%) Flow (ml/min) UV (nm) 
0 90 10 1  
220 nm 60 30 70 1 
65 30 70 1 
70 90 10 1 
 
Table 2.3 Standard method for preparative HPLC 
Time (min) Buffer A (%) Buffer B (%) Flow (ml/min) UV (nm) 
0 90 10 10  
 
220 nm 
60 60 40 10 
65 30 70 10 
70 30 70 10 
75 90 10 10 
 
2.2.2 Synthesis of ααAAs 
Facile synthetic routes for ααAAs are required to obtain enough amino acid for solid 
phase peptide synthesis of designed inhibitor peptides. Syntheses followed previously published 
procedures with some slight modifications. Fmoc reactions were carried out following Bolin 
procedure.2  
2.2.2.1 Synthesis of Nα− Protected Dipropylglycine(Dpg) 
2.2.2.1.1 5, 5-Dipropylhydantoin (1a) 
Previously synthesized following bucherer-Bergs protocol for aldehydes or ketones.3, 4 A 
solution of 4-heptanone (20 g, 175.2 mmol), potassium cyanide (24 g, 367.6 mmol), and 
ammonium carbonate (37.2 g, 385.2 mmol) in methanol (100 mL) and water (100 mL) was 
heated at 50 ºC in a capped vessel for 36 h. The precipitated solid was filtered and washed with a 
+small portion of water and dried in air to yield the hydantoinhydantoin 1a as an off-white 
powder (25.0 g, 80% yield). 1HNMR (250 MHz, CD3SOCD3) δ: 10.55 (s, 1H), 7.81 (s, 1H), 
1.69 -1.57 (m, 4H), 1.43 -1.38 (m, 2H), 1.22 -1.19 (m, 2H), 0.88 - 0.85 (t, 6H). 13C NMR (75 
MHz, DMSO-d6) δ: 178.89, 157.71, 76.07, 66.49, 17.11, 14.77.  
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2.2.2.1.2 2, 2-Dipropylglycine (2a) 
The hydantoin 1a (18 g, 97.8 mmol) was suspended in 5 N NaOH (272 mL, 1.36 mol), 
and refluxed for 40 h. The mixture was then cooled and acidified to pH 6.5 with concentrated 
HCL. The precipitate that formed was then filtered, concentrated in vacuo, and further washed 
with a small portion of acetone to remove the unreacted hydantoin. Both the filtrate residue and 
the solid that precipitated out upon acidification were extracted with warm ethanol several times. 
Dipropylglycine (Dpg) was obtained as a white solid upon removal of ethanol in vacuo.  The free 
amino acid 2a was purified using Dowex 50X8-400 ion exchange resin, packed tightly in a 
büchner funnel connected to suction pressure. The resin was activated by rinsing with 2N HCl 
and then with water until the eluent was neutral.  Dipropylglycine was dissolved in 2 N HCl, 
added to the activated resin, and rinsed with water (3 L) to remove all inorganic salts that were 
formed during acidification.  The amino acid bound to the resin was washed off the resin with 2 
N NH4OH (2 L) and solvent removed in vacuo to yield 2a (15.6 g, 75%). Anal. Calcd. for 
C10H21NO2: C, 60.35; H, 10.76; N, 8.80; Found: C, 60.14; N, 10.73; N, 8.73.  1HNMR (250 
MHz, CD3SOCD3) δ: 7.34(s, 2H), 1.51-1.10 (m, 8H), 0.87-0.78 (t, 6H).  
2.2.2.1.3 9-Fluorenylmethoxycarbonyl-2, 2-dipropylglycine (3a) 
Trimethylsilylchloride (7.27 mL, 57.26 mmol) was added in one portion to a suspension 
of 2a (4.52 g, 28.63 mmol) in 45 mL of anhydrous CH2CL2, and refluxed for 8 h. The mixture 
was cooled in an ice bath then, N, N-diisopropylethylamine (9.85 mL, 57.26 mmol) and Fmoc 
chloride (6.73 g, 26.02 mmol) were added. The solution was stirred at 0˚C for 30 min before the 
reaction was allowed to warm up to room temperature and stirred further for 24 h. The resulting 
mixture was concentrated in vacuo to provide an oil that was dissolved in DI water (60 mL), 
acidified to pH 2 with 12 N HCl, and then extracted with ethyl acetate (3×60 mL).  The 
28 
 
combined organic layers were dried over anhydrous MgSO4 and concentrated in vacuo to 
provide a yellow solid which was triturated in hexanes to afford  a white solid product 3a (8.51 
g, 86%). 1HNMR (250 MHz, CD3SOCD3) δ: 10.68 (s, 1H), 7.91-7.88 (d, 2H), 7.71 - 7.69 (d, 
2H), 7.44-7.29 (m, 4H), 6.95 (s, 1H), 4.28 - 4.21 (m, 3H), 1.76 - 1.74 (m, 4H), 1.20 - 1.10 (m, 
2H), 0.86 - 0.82 (m, 6H). Anal. Calcd. for C25H31NO4: C, 74.42; H, 7.13; N, 3.67. Found: C, 
72.57; H, 7.30; N, 3.80. 
2.2.2.2 Synthesis of Nα-Protected Dibenzylglycine  
Dibenzylglycine was  synthesized following previously reported protocol  from ethyl nitro 
acetate.3 
2.2.2.2.1 Ethyl 2-benzyl-2-nitro-3-phenylpropanoate (1b)  
To a solution of ethyl nitroacetate (1.0 g, 7.51 mmol) in dry DMF (5 mL) was added 
DIEA (2.0 g, 15.4 mmol) and Bu4N+Br– (0.24 g, 0.75 mmol).  To this clear yellow solution, 
benzyl bromide (2.6 g, 15.4 mmol) was added and the reaction spontaneously warmed to 60 ºC 
over 5 min.  After 20 min., DIEA•HBr precipitated out of solution.  After 1 h, DIEA•HBr was 
filtered, washed with ether (100 mL), and the combined filtrate washed with H2O (5 x 50 mL).  
The organic layer was dried (Na2SO4) and ether removed under vacuo to provide a yellow oil, 
which was of sufficient purity to be used in further reactions or could be purified by silica gel 
chromatography using pentane : ether (90:10) to provide a white solid 1b, yield 0.55 g (55%).  
2.2.2.2.2 Ethyl 2, 2-dibenzylglycine ester (2b)  
To a solution of nitro ester 1b (0.51 g, 1.80 mmol) in glacial AcOH (1mL) and absolute 
ethanol (10 mL), a catalytic amount of Raney Nickey 50 % (w/v) was added.  The resulting 
mixture was reduced over hydrogen gas; pressure (50 psi) for 24 h. Raney Nickel was filtered 
over Celite cake and washed with 30 mL of ethanol. Ethanol was removed in vacuo and the 
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crude product dissolved in 30 mL diethyl ether, washed with 10 mL (3X) saturated sodium 
carbonate, and then with 10 mL (3X) brine.  The resulting organic fraction was dried over 
anhydrous sodium sulfate for 45 min and ether removed under vacuo to give the crude product 
(0.32 g) which was purified via silica gel column chromatography using ethyl acetate: hexane 
(70:30). 
2.2.2.2.3 2, 2-Dibenzylglycine (3b)  
A suspension of dibenzylglycine ester 2b (0.90 mg, 0.35 mmol) in 2 M KOH (50 mL) 
and ethanol (25 mL) was refluxed under argon for 24 h.  The resulting mixture was concentrated 
to 20 mL in vacuo and acidified to pH 6.5 using 12 N HCl. The white precipitate formed was 
filtered, washed with cold water (5 mL), and air dried to provide the free amino acid  which was 
purified via ion exchange chromatography using cationic exchange Dowex 50X8-400 resin to 
afford 3b (430 mg, 1.68 mmol). 1HNMR (250MHZ, CD3OD) σ: 7.26 - 7.3 (10H), 3.45 (d, 2H) 
2.87 (d, 2H), 1.27 (s, 2H), Anal. Calcd for C16H17NO2: C, 75.27; H, 6.71; N, 5.48. Found: C, 
75.12; H, 6.66; N, 5.59. 
2.2.2.2.4 Nα-(9-Fluorenylmethoxycarbonyl)-2, 2-dibenzylglycine (4b)  
To a suspension of 3b (430 mg, 1.68 mmol) in dry DCM (6.45 mL) was added Trimethylsilyl 
chloride (108.64 mg, 3.36 mmol) and refluxed under argon for 8 h.  The mixture was cooled to 
0ºC in an ice bath and DIEA (129.25 mg, 1.68 mmol) and Fmoc-Cl (390 mg, 1.51 mmol) were 
added.  The reaction was allowed to warm to 25 ºC and stirred for 30 h.  The resulting mixture 
was concentrated in vacuo to provide a yellow solid, which was dissolved in water (30 mL), 
acidified to pH 2.0 with 12 N HCl, and extracted with ethyl acetate (3 x 35 mL).  The combined 
ethyl acetate fractions were dried over anhydrous magnesium sulfate and concentrated in vacuo 
to provide a light yellow solid. The crude product was triturated in hexanes to afford a white 
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solid 4b in75 % yield. 1HNMR (250MHZ, CDCL3) σ: 7.82-7.12 (m, 18H), 5.51 (s, 1H), 4.50 (d, 
J = 7 Hz, 2H), 4.30 (t, J = 7.0Hz, 1H), 3.93 (d, J = 13.6Hz, 2H), 3.25 (d, J = 13.6Hz, 2H). 
13CNMR (75 MHz, CDCL3) σ: 177.49, 155.03, 144.21, 141.74, 136.17, 130.13, 128.86, 128.17, 
127.53, 125.60, 124.48, 120.42, 67.08, 66.94, 47.67, and 42.17. Anal.Calcd. for C31H27NO4: C, 
77.96; H, 5.70; N, 2.93. Found: C, 78.06; H, 5.63; N 2.47. 
 2.2.2.3 Synthesis of Nα-Protected Diisobutylglycine  
Diisobutylglycine was synthesized following previously reported protocol5 
2.2.2.3.1  Ethyl 2, 2 – Bis (2-methylallyl)-2-nitroacetate (1c). 
  To a solution of ethyl nitro acetate (10.0 g, 75.1 mmol) in dry THF (110 mL) were added 
2-methylallyl acetate (18.0 g, 157.1 mmol) and Pd(PPh3)4 (4.5 g, 3.9 mmol). After 15 min, DIEA 
(20.1 g, 157.1 mmol) was added, and the reaction stirred under argon for 8 h at 50 °C. The 
resulting solution was filtered over Celite while washing with THF (2 ×120 mL). The filtrate was 
concentrated, dissolved in 75 mL of EtOAc, and washed with 10% K2CO3 (50 mL). To the 
organic layer was added 6 g of PS-PPh3 (1.3 mmol/g) Argonaut resin and the mixture was 
shaken for 25 min. The resin was filtered and the filtrate purified via column chromatography 
using hexane : EtOAc ( 80:20) to provide a light yellow oil 1c (7.65g, yield 97%). 1H NMR (250 
MHz, CDCl3) σ: 4.94 - 4.92 (m, 2H), 4.78 - 4.77 (m, 2H), 4.26 - 4.18 (q, 2H), 3.0-2.99 (m, 4H), 
1.69 (m, 6H), 1.29 - 1.23 (t, 3H). 
2.2.2.3.2  Ethyl 2, 2-Diisobutylglycine Ester (2c). 
To a solution of 1c (17.64g, 72.9 mmol) in absolute ethanol (30 mL) were added glacial 
acetic acid (4 mL) and a 50 % (w/w) slurry of Raney nickel in water (6.0 g). The reaction was 
hydrogenated over H2 gas (50 psi) for 24 h. The resulting solution was filtered carefully over 
Celite while washing with EtOH (2 x 50 mL). The solvent was removed in vacuo and the crude 
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dissolved in diethyl ether (80 mL), washed with saturated sodium carbonate (60 mL), and brine 
(60 ml). The resulting organic fraction was dried over anhydrous sodium sulfate and reduced 
under vacuo to afford 2c (14.2g, 90% yield).  1H NMR (250 MHz, CDCl3) δ: 4.08 - 4.0 (q, 2H), 
1.67 -1.59 (m, 6H), 1.40 -1.35 (m, 2H), 1.21-1.16 (t, 3H), 0.85 - 0.82 (m, 6H), 0.73 - 0.71 (m, 
6H). 
2.2.2.3.3   2, 2-Diisobutylglycine(3c).  
A suspension of 2c (14.2 g, 65.7 mmol) in 3 M KOH (200 mL) and ethanol (100 mL) 
was refluxed under N2 for 24 h. The resulting mixture was concentrated to 100 mL and acidified 
to pH 6.5 with 12 N HCl. The solvent was evaporated and the residue re-dissolved in a minimum 
amount of water (~50 mL). The mixture was added to an activated Dowex 50X8-400 ion-
exchange resin (600 g) washed with 2 L of water and then eluted with methanol (300 mL) and 2 
N NH4OH (2 L). The collected 2 N NH4OH fractions were evaporated in vacuo to give the free 
amino acid 3c (9.5g, yield 83%) as a white powder. mp 224 - 227 ºC; 1H NMR (250 MHz, 
DMSO-d6) δ 7.3 (s, 2H), 1.76-1.70 (m, 2H), 1.62-1.43 (m, 4H), 0.86-0.83 (m, 12 H); 13C NMR 
(75 MHz, DMSO-d6) δ: 172.2, 62.7, 45.9, 25.0, 23.3, 23.0; Anal. Calcd. for C10H21NO2: C 
64.13; H, 11.30; N, 7.48. Found; C, 64.39; H, 11.84; N 7.60. 
2.2.2.3.4 Synthesis of Nα-Protected Dibg. N-(9-Fluorenylmethoxycarbonyl)-2, 2-
diisobutylglycine(4c)  
 
Trimethylsilychloride (8.8 g, 81.0 mmol) was added to a suspension of the amino acid 3c 
(7.4 g, 39.6 mmol) in dry CH2Cl2 (80 mL) and refluxed under N2 for 8 h. The mixture was 
cooled to 0°C, and DIEA (10.5 g, 81.0 mmol) and Fmoc-Cl (10.0 g, 38.6 mmol) were added. The 
reaction was allowed to warm to 25 °C and stirred for 20 h. The resulting mixture was 
concentrated in vacuo to provide a yellow solid that was then dissolved in EtOAc (80 mL). To 
this mixture, water was added (40 mL), and the solution acidified to pH 2.0 with 2 N HCl. The 
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separated organic layer was dried over magnesium sulfate and concentrated in vacuo to provide a 
light yellow solid. The crude product was triturated in hexanes to afford a white solid 4c (13.7 g, 
88% yield): mp 132-133 °C; 1H NMR (250MHz, DMSO-d6) δ: 7.90-7.28 (m, 8H), 6.48 (s, 1H), 
4.33 (d, J ) 6.7 Hz, 2H), 4.20 (t, J ) 6.7 Hz, 1H), 2.03-1.97 (m, 2H), 1.63-1.48 (m, 4H), 0.80-0.76 
(m, 12 H); 13C NMR (75 MHz, DMSOd6) δ:175.7, 153.4, 143.7, 140.7, 127.6, 127.0, 125.0, 
120.1, 64.9,61.5, 46.7, 43.6, 23.8, 23.7, 23.1. Anal. Calcd for C25H31NO4: C, 73.32; H, 7.63; N, 
3.42. Found: C, 73.50; H, 7.76; N 3.52. 
2.2.3 Peptide Synthesis.  
2.2.3.1 General 
 All peptides were synthesized by solid phase peptide synthesis (SPSS) on PAL-PEG-PS resin 
(0.16-0.22 mmol/g) or Rink amide resin (0.52 mmol/g) either manually or on automated pioneer 
peptide synthesizer.   
2.2.3.2 Attachment of the First Residue on the Resin. 
The resin is swollen in DMF or DCM for 20 min and drained before use. The first amino 
acid residue attached to the resin linker is always coupled twice to increase the overall peptide 
yield and prevent formation of C-terminally related truncated peptides. 
2.2.3.3 Removal of the Fmoc Protective Group 
A solution of 5 % piperidine and 2 % DBU in DMF (4 ml/g resin) is added to resin. The mixture 
is shaken for 2 min at room temperature and drained. This is repeated for 5 and 10 min before the 
resin is washed with DMF (5×1 mL) and DCE (5×1mL).  
2.2.3.4 Amino Acid Coupling 
 Amino acid (4 equiv) and HBTU/HOBt (4 equiv each) is dissolved in 0.5 M DIEA and added to 
the unprotected resin (1 equiv) for 1 hr while shaking. The coupling mixture is drained and resin 
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washed with DMF (5×1 mL), and DCM (5×1 mL). For difficult couplings especially ααAAs, the 
stronger activating agents such as PyAOP/HOAt or HATU/HOAt were used and couplings 
carried out using DCE: DMF (2:1) as solvent and at elevated temperature (50°C). Small 
quantities of resin are tested for un-reacted amine with bromophenol blue test. If the test is 
positive, the coupling reaction is repeated 
2.2.3.5 N-acylation of ααAAs Using Symmetrical Anhydrides.   
10.0 equiv of amino acid (relative to resin) is dissolved in dry DCM under argon (drops of DMF 
may be needed for complete dissolution) and cooled to 0 °C. 5.0 equiv of DIC (relative to resin) 
are slowly added. The mixture is stirred for 30 min before DCM is evaporated and residue 
dissolved in a minimum amount of DCE: DMF (9:1). The mixture is added to the resin for 8 hr at 
50°C while shaking. Resin is filtered, washed with (5×1 mL), (5×1 mL) and small quantities of 
resin are tested for un-reacted amine with bromophenol blue test. If the test is positive, the 
coupling reaction is repeated 
2.2.3.6 Capping of Unreacted Sites 
Resin is capped specifically after difficult couplings using 0.2 M acetic acid and 0.28 M 
DIEA (24 mL) for 2 hr to terminate deletion sequences arising from unreacted sites. Capping 
solution is removed and resin washed with DMF (10 ×1mL).  
2.2.3.7 Peptide Cleavage 
Resins were treated with standard cleavage solution (trifluoroacetic acid: 
triisopropylsilane: water: phenol (8.8:0.2:0.5:0.5) at room temperature for 2 h to cleave the 
peptide from the solid support. After filtration, the filtrate is diluted in cold ethyl ether and 
allowed to co-precipitate overnight.  The precipitate was centrifuged at 40,000 rpm, washed with 
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cold ethyl ether, and centrifuged for ten minutes (3x). The supernatant was filtered and the 
resulting pellet allowed to dry overnight yielding the crude product. 
2.2.3.8 Fmoc Analysis 
 Coupling yields for each step were determined by detection of Fmoc-piperidine conjugate 
using a UV spectrophotometer at 300 nm and the absorbance reading was used to calculate the 
yield based on the new resin substitution as compared to the original. Also bromophenol blue 
(10% in acetonitrile) was used to monitor the presence of free amine; blue color, positive test 
while yellow color is a negative test. 
2.2.3.9 Circular Dichroism Measurements 
All measurements were carried out using an Aviv Circular Dichroism Spectrometer 
Model 62DS with Igor plotting software.  The CD spectra are averages of three scans made at 
1.00 nm intervals acquired from 250 nm to 190 nm (UV Abs range) recorded at 25 0C.    
2.3 Results and Discussion 
2.3.1 Synthesis of ααAAs 
The ααAAs, Dibg, Dbg, and Dpg are achiral analogues of the natural amino acids 
leucine, phenylalanine, and alanine respectively (Scheme 1).  The most common method of 
synthesizing ααAAs is via Bucherer-Bergs or Strecker syntheses,6 yet only Dpg was 
successfully synthesized using this method (Scheme 2). The only modification to this procedure 
was the longer reaction time, and improved work up procedures during the Fmoc reaction of 2a 
which resulted in dramatic increase in yield of 3a (68%) to 86%.  The other amino acids, Dbg, 
and Dibg failed because they form sterically hindered hydantoins, which are extremely difficult 
to hydrolyze to free amino acids even under extremely harsh conditions.   
 
35 
 
Scheme1 
 
This prompted development of other alternative synthetic routes to ααAAs such as glycine anion 
and cation equivalents.7  Nitroacetate esters have long been recognized as potentially useful 
synthetic intermediates for the preparation of amino acids as well as other biologically 
significant compounds.8  
Scheme 2  
 
Fu et al, devised a strategy that uses commercially available ethyl nitro acetate, tertiary base, and 
a catalyst to synthesize the dialkylated nitro esters such as ethyl 2, 2-dibenzylglycine ester  1b 
(Scheme 2). The nitro ester was then reduced to the free amine 2b using hydrogen gas in 
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presence of Raney nickel, followed by hydrolysis of the ester using KOH/EtOH to afford the free 
amino acid 3b. The N-terminal of 3b was protected with Fmoc protecting group to yield 4b, 
which was suitable for SPPS. 
Scheme 3 
 
  The overall yields were consistent with those reported by Fu (Scheme 3). The only 
modification to this method was the workup procedure for extracting 4b from the reaction 
mixture. We found that some of the product was washed off during ether washings. To solve 
this, the crude product was directly dissolved in water, acidified to pH 2 (if necessary), and 
extracted with ethyl acetate to yield Fmoc protected dibenzyl glycine 4b in an improved yield of 
75 %. Most of the intermediate synthetic steps were high yielding except the initial dialkylation 
of ethyl nitroacetate. The low yields dropped further to 30% when the reaction was scaled up (30 
%). The reaction conditions, change of base, and order of addition were optimized in an effort to 
improve the yields, and results are presented in Table 2.4. The overall strategy is to have a 
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synthetic route that is simple, reproducible, and has the ability to be scaled up in order to 
synthesize enough amino acid for peptide synthesis.  
Table 2.4. Alkylation of ethyl nitroacetate. 
Ester Bromide Base Scale of Ester 
(mmoles) 
Order of 
addition 
 %Yield  
 
Temp° C 
O2NCH2CO2Et PhCH2Br DIEA 7.51 Base first 50 Room temp 
O2NCH2CO2E PhCH2Br DIEA 7.51 Base first 55 0 
O2NCH2CO2E PhCH2Br DIEA 7.51 Base last 44 Room temp 
O2NCH2CO2E PhCH2Br DIEA 7.51 Base first 
Excess solvent 
57 0 
O2NCH2CO2Et PhCH2Br DIEA 37.5 Base first 30  Room temp 
 O2NCH2CO2Et PhCH2Br t-BuO-K+ 7.51 Base first 52.2 Room temp 
 
The yields were slightly improved when the reaction was carried out at 0° C as compared to 
room temperature (Table 2.4).  Alkylation of ethyl nitroacetate is an exothermic reaction, and 
explains why higher yields are observed at 0° C as compared to room temperature. Changing the 
order of addition between the base and benzyl bromide showed no significant effect on the yield 
of dialkylated product. Further investigations of the extraction procedure, reveals that some of 
the product was detected in solvent waste during rotary evaporation, bringing into question the 
stability of 1b.  This is supported by the improved yields obtained when benzyl bromides having 
electron withdrawing groups were used. Microwave irradiation technology has been introduced 
to organic synthesis, and in particular has been successfully employed to hydrolyze sterically 
hindered hydantoins.4 Thus Dbg, which previously failed because of hydantoin hydrolysis 
problems, can now be synthesized via Bucherer-Bergs or Strecker syntheses, the most common 
method of synthesizing ααAAs.   
 Synthesis of Dibg was accomplished via Palladium mediated diallylation of ethyl 
nitro acetate to obtain the dialkylated nitro ester 1c in 97% yield (Scheme 4).9 The other 
synthetic steps were the same as for Dbg (scheme 3). This synthetic route is facile and efficient 
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as depicted by the high yields in all the reaction steps. The only modification to this procedure 
was the amount of palladium catalyst used, which was reduced to 1% without affecting the yield 
of 1c. This also helps to reduce the amount of polystyrene bound triphenyl phosphine needed to 
scavenge the palladium catalyst. This leads to a more facile separation in addition to cost 
reduction.  
Scheme 4 
 
2.3.2 Peptides Synthesis 
Incorporation of ααAAs is a recognized way of inducing secondary structure in peptides.10 
Peptides without ααAAs were easily synthesized using HBTU or TBTU/HOBt coupling 
chemistry in good yields and purity at room temperature. Peptides incorporating ααΑAs were 
coupled using various coupling chemistries. All natural amino acids before any ααAAs were 
coupled using HBTU or TBTU/HOBT, but those incorporated after ααAAs were generally 
difficult to couple, hence coupled using PyAOP/HOAt activating agent. The less sterically 
hindered Dpg has been incorporated into peptides via conventional coupling methods in good 
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yields.11 Coupling of Dpg were accomplished using PyAOP/HOAt chemistry at 50° C and were 
re-coupled.  Incorporation of the more sterically hindered ααAAs such as Dbg and Dibg into 
peptides was more problematic. Fu et al9 reported optimal coupling techniques necessary for the 
incorporation of sterically hindered Dbg and Dibg into peptide sequences. Coupling of Dbg was 
achieved using PyAOP/HOAt chemistry while Dibg was coupled via HATU/HOAt chemistry at 
elevated temperature and were re-coupled.  
The real difficulty mainly stems from the inefficient acylation of the ααAAs N-termini. 
Fu also reported that acylation of the N-terminus of these ααAAs is possible via the symmetrical 
anhydride method in the absence of a base.12However, we continue to have a lower coupling 
yields for acylation of N-terminus of ααAAs especially Dbg. Design of peptides incorporating 
ααAAs, places valine after Dbg, which has an isopropyl side chain that we suspect is responsible 
for the lower yields. Lysine was easily coupled to Dibg via symmetrical anhydrides. Lysine has 
n-side chain as compared to sterically hindered valine.  
The low coupling could be because of poor yields of valine (30 %) as compared to lysine 
(60%) symmetrical anhydrides. Coupling yields for each coupling step were determined by 
Fmoc analysis using a UV spectrometer at 300 nm.  Also, bromophenol blue was used to monitor 
any unreacted sites.  Blue color is a positive test for presence of free amine and yellow is 
negative test.  All the reaction conditions, equivalents, solvents, ratios, and bases for coupling of 
each amino acid are listed in Table 2.5.  The peptide was cleaved from the resin using 
trifluoroacetic acid, precipitated out using cold ether, dried, and analyzed using analytical HPLC 
and MALDI-MS or ESI.  The various AAMPs were synthesized following a general synthetic 
route (Figure 2.1).  Peptides without ααAAs were generally synthesized in good yields and 
purity as analyzed by analytical HPLC.   
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Figure 2.1.  General synthetic route for the synthesis of AAMPs 
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Table 2.5.  General reagents and conditions for coupling of various amino acids to a 
peptide sequence 
 
Peptide AAMP-19 is presented as an example to show clean synthesis for peptides 
without ααAAs incorporated in their sequence. The chromatogram for AAMP-19 (Figure 2.2) 
shows a single peak with Rt = 26.5 min, and was confirmed by ESI-MS as the expected mass ion 
peak (837.1 mass units).  Purification and mass spectrometry data for various AAMPs are 
presented in  Table 2.6. 
Synthesis of peptides incorporating ααΑAs amino acids were more challenging. For 
example, our first attempt to synthesize AAMP-2 failed as no peaks from analytical HPLC crude 
(Figure 2.3A) matched the calculated mass ion peak of 1652 mass units for AAMP-2. The major 
peak at Rt = 32.67 corresponded to the peptide (DbgPheDpgK6) with Val, Leu, and Lys deleted. 
This shows the difficulty of acylating the C-terminus of ααAAs. One major reason for the failed 
synthesis was the low concentration of the coupling reagents (0.08M). The peptide was re-
synthesized using 0.3M concentrations of coupling reagents. Analytical crude HPLC spectrum 
(Figure 2.3B) for the re-synthesized peptide showed a peak at Rt = 36.5 which corresponded 
with the expected molecular ion peak of 1652 mass units. 
         
Amino 
acid  
Resin 
equiv. 
Amino 
acid 
equiv. 
Activator Activator 
equiv. 
 base  Base 
equiv. 
Solvent Time 
(min) 
Temp 
°C 
Natural 
amino 
acids 
1 4 HBTU/HOBt 4.0 DIEA 8.0 DMF 3 25 
Dpg, 
Dbg 
1 4 PyAOP/HOAt 4.0 DIEA 8.0 DMF 3 50 
Dbg 1 4 PyAOP/HOAt 4.0 DIEA 8.0 DCE:DMF 
(2:1) 
8 50 
Dibg 1 4 HATU/ HOAt 4.0 DIEA 8.0 DCE:DMF 
(2:1) 
8 50 
acylation 
of 
ααAAs 
1 2 DCC, DIC, 
BOP-Cl 
1.0 No 
base 
- DCE:DMF 
(9:1) 
8 50 
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Figure 2.2.  HPLC chromatograms of AAMP-19 [A] Analytical HPLC for pure peptide; [B] 
Analytical HPLC for peptide synthesized using microwave irradiation; [C]  Analytical HPLC for 
peptide synthesized using conventional heating method. HPLC conditions for A: 20-40% B in 30 
min, 10-70 % B in 80 min for B  and 10-70% B in 60 min.  
 
However, the major peak at Rt = 43.5 matched the molecular ion peak for deletion peptide 
detected earlier. Further improvements in coupling conditions such as change of coupling 
solvents, coupling reagents, were unsuccessful. The real problem with the coupling arises from 
poor acylation of the sterically hindered ααAAs, and especially with valine. Couplings yields 
showed were slightly increased when valine was replaced with less sterically hindered alanine as 
measured by UV Fmoc analysis.  To improve the yields microwave irradiation shown recently to 
exponentially increase rate of reactions resulting in higher yields in a short time was employed 
for difficult couplings.   
 Figure 2.3. HPLC chromatograms of AAMP
spectrum 2nd trial after coupling steps 
60 min and 10-50 % B in 60 min for 2
 
Microwave technology has been used in 
chemical reactions that require heating.
peptide synthesis was reported in 1992.
solvents to convert electromagnetic radiation into heat. Growi
conventional synthesis have a propensity to aggregate. However, during microwave irradiation, 
the peptide chains are in constant random motion breaking up any aggregation.  Microwave 
heating is increasingly used in peptide synthesi
increased in a shorter time.  Microwave heating was applied to coupling of sterically hindered 
amino acids and its acylation on the N
and Val using microwave irradiation, and various coupling methods were investigated to 
optimize efficient synthesis of AAMPs. 
synthesize AAMPs with ααAAs incorporated into their sequences.
(KLVDbgFAK6) with Dbg inv
temperature. 
 
43 
-2, [A] Analytical HPLC 1st trial. [B] Analytical 
was optimized.  HPLC conditions for 1st trial: 10
nd
 trial.  
organic chemistry since early 1980 for various 
13-17
 The first application of microwave technology to 
18
 Microwave irradiation takes advantage of certain 
ng peptide chains during 
s because coupling yields 
-terminus. We found increased yields for Dbg coupling 
 Microwave irradiation technology was used to 
  Synthesis of AAMP
olved coupling the first 8 natural amino acids at room 
     
-70% B in 
are significantly 
-8 
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Table 2.6. MALDI-MS results of inhibitor peptides analogs. 
Entry AAMPs Sequence  Exact 
mass  
Observed  
(M+H)+ 
tR 
(min) 
% Peptide  
content 
1 AAMP-0 KLVFFK6 1419.98 1420.99 20.1 67 
2 AAMP-1 KDibgVDbgFDpgK6 1707.21 1708.21 24.6 51 
3 AAMP-2 KLVDbgFDpgK6 1651.14 1652.15 23.8 39 
4 AAMP-3 KDibgVFFDpgK6 1617.16 1618.16 23.9 50 
5 AAMP-4 KDibgVDbgFAK6 1637.13 1638.17 25.6 52 
6 AAMP-5 KDibgVFFAK6 1547.08 1548.09 22.9 72 
7 AAMP-6 KLVAFDpgK6 1561.10 1562.10 21.9 51 
8 AAMP-7 KLVDbgFAK6 1581.06 1582.06 25.4 49 
9 AAMP-8 KLDpgFFAK6 1533.06 1535.07 23.1 49 
10 AAMP-9 KLVFDpgK6 1414.03 1415.05 19.5 50 
11 AAMP-10 DibgVFFAK6 1418.99 1419.99 21.2 49 
12 AAMP-11 RGKLVFFGR 1077.66 1078.67 27.1 64 
13 AAMP-12 KGKLVFFGK 1021.63 1022.65 24.0 100 
14 AAMP-13 EGKLVFFGE 1023.54 1024.54 24.5 61 
15 AAMP-14 mPEGGKLVFFGmPEG 1055.56 1056.61 24.1 55 
16 AAMP-15 RRRGKLVFFGRRR 1702.06 1703.07 20.6 80 
17 AAMP-16 KLVFFGR 864.53 865.54 28.1 62 
18 AAMP-17 KLVFFGmPEG 853.51 854.52 30.4 83 
19 AAMP-18 KLVFFGK 836.53 837.54 23.9 71 
20 AAMP-19 RGKLVFF 864.53 865.54 24.6 48 
21 AAMP-20 KLVFFDpgGK 977.64 978.65 26.2 60 
22 AAMP-21 KGKDibgVFFGK 1077.71 1079.1 24. 58 
23 AAMP-22 KDibgVFFDpgGKKK 1289.88 1290.90 27.2 53 
24 AAMP-23 KKKGKLVFFDpgGKKK 1676.12 1677.14 21.0 57 
25 AAMP-24 KDibgVFFAGKKK 1120.80 1121.76 27.6 62 
26 AAMP-25 KLVFFFDpgGKKK 1233.82 1234.84 23.0 65 
27 Aβ16-22m KL(Me)VF(Me)FA(Me)E 895.84 896.85 22.88 66 
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The other amino acids were coupled using microwave heating.  Conventional synthesis of 
the AAMP-8 was carried out to compare the two methods. Analysis of their analytical spectrums 
(Figure 2.4) shows an increase in the peptide peak when microwave heating (Figure 2.4B) was 
used (Rt = 34.5) as compared to the conventional heating (Figure 2.4C) method (Rt = 36.5).  
                            
Figure 2.4 HPLC chromatograms of AAMP-7.  [A] Analytical HPLC for pure peptide; [B] 
Analytical HPLC for peptide synthesized using microwave irradiation; [C]  Analytical HPLC for 
peptide synthesized using conventional heating method. HPLC conditions for A: 20-40% B in 30 
min, 10-70 % B in 60 min for B and C.  
 
 
Coupling of the carboxyl group of ααAAs Dbg to a growing peptide chain and acylation 
of the N-terminal ααAAs was previously shown to be difficult in both solution and solid phase 
peptide synthesis.5  Various coupling methods were investigated for coupling of Dbg and Val 
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during synthesis of AAMP-7 by determining the yields using UV analysis at 300 nm of Fmoc-
deprotection.  The first eight amino acids were coupled via automated peptide synthesis and 
coupling of Dbg and Val, which follows, was then studied using the various coupling methods 
(Table 2.7).  
Table 2.7 Coupling of  Dbg and then Val onto Phe-Phe-Ala-(Lys)6 (AAMP-7) 
 Entry Coupling 
agent 
Base Solvent Time temp yield Equiv. Conc. 
(M) 
Dbg 
 
 
 
1 PyAOP/HOAt DIEA DMF 20 min 95 90 5 0.3 
2 PyAOP/HOAt DIEA DMF 10 min  95 80 5 0.3 
3 PyAOP/HOAt collidine DMF 10 min  95 35 5 0.3 
4 PyAOP/HOAt DIEA DMF:DCE 
(3:1) 
5 min  110 92 5 0.3 
5 HATU/HOAt DIEA DMF:DCE 
(3:1) 
5 min 110 72 5 0.3 
6 PyAOP/HOAt DIEA DMF 12 h 50 50 5 0.3 
7 PyAOP/HOAt DIEA DMF 12 h 50 30 4 0.3 
8 PyAOP/HOAt DIEA DMF 12 h 50 50 8 0.3 
9 PyAOP/HOAt DIEA DMF 12 h 50 55 5 0.4 
VAl 10 DCC  DMF:DCE 1 h 95 61 5  
11 DCC  DMF:DCE 20 min 95 45 5  
12 BOP-Cl DIEA DMF:DCE 20 min 95 35 5  
13 DIC  DMF:DCE 20 min 95 45 5  
14 DCC  DMF:DCE 12 h 50 35 20  
15 DiC  DMF:DCE 12 h 50 40 20  
16 BOP-Cl  DMF:DCE 12 h 50 30 20  
 
Higher yields for Dbg and Val coupling were obtained in a short time when microwave 
irradiation was used as compared to conventional heating.  Coupling of Fmoc-Dbg-OH onto the 
N-terminus of the Phe on the resin using PyAOP/HOAt was more effective than HATU/HOAt 
(entry 4 and 5).  The strength of the base used affected the coupling yields of Dbg where higher 
yields were realized when DIEA (entry 2) was used as compared to collidine (entry 3).  There 
was no significant change in yields with longer coupling time (entry 1 and 2), temperature (entry 
1 and 4, and solvent mixture (entry 1 and 4). Higher Dbg coupling yields at room temperature 
were observed with increased concentration of coupling agents/amino acid (entry 8 vs 9) or 
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equivalents of amino acid (entry 7 vs 8).  Acylation of Dbg N-terminus was previously coupled 
with higher yields using Fmoc-Val symmetric anhydride as compared to PyAOP or HATU 
coupling methods. Higher yields were observed for Val coupled earlier (second) in the peptide 
sequence as compared to the lower yields we report for Val coupled later in the synthesis (tenth). 
Yields for Val were increased when microwave irradiation (entry 10-13) was used as compared 
to conventional heating (entry 14-16). Fmoc-Val-OH symmetrical anhydrides obtained from 
DCC (entry 10, 11) or DIC (13) used to acylate Dbg N-terminus gave higher yields as compared 
to BOP-Cl (entry 12).  Similarly, higher yields for coupling Val using Fmoc-Val symmetrical 
anhydrides were observed when microwave irradiation was used as compared to conventional 
heating.  
 
Figure 2.5.  HPLC chromatograms of AAMP-21.  [A] Analytical HPLC for pure peptide; [B] 
Analytical HPLC for peptide synthesized using microwave irradiation; [C]  Analytical HPLC for 
peptide synthesized using conventional heating method.  HPLC conditions for A: 20-40% B in 
30 min, 10-50 % B in 60 min for B and10-70 % B in 60 min for C.  
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Another example to show the success of microwave technology was synthesis of AAMP-
21 (KDibgVFFGK) containing Dibg.  The HPLC spectrum from peptides synthesized by 
conventional synthesis showed two closely related peaks (Figure 2.5C).  The peak with Rt = 30.5 
matched the expected mass ion peak.  The other taller peak Rt = 33.8 corresponded to deletion of 
Lys, consistent with the problem in acylating the N-terminus of ααAAs. However, using 
microwave irradiation method, the deletion peptide observed in conventional heating 
disappeared (Figure 2.5B) and a peak (37.8 min) that corresponded to the expected molecular ion 
increased.  
2.3.3 Conformational Studies of Migators 
Circular dichroism studies of sample of peptides were carried out to determine their aggregation 
behavior. The effect of the various AAMPs on Aβ assembly into β-sheet structures will be 
discussed later in chapters 3 and 4. The CD spectra for all AAMPs showed a characteristic 
random coil structure as shown by a large negative band near 200 nm and small positive band 
near 220 nm. There was no transition from random coil to β-sheet observed for all the AAMPs 
synthesized with varying concentrations.  This suggests that the propensity for the AAMPs to 
aggregate is minimal, and that they do not misfiled or unfold at higher concentrations through a 
multistep folding process.  There was no significant difference observed in the CD signal of 
mitigators containing ααAAs (Figures 2.6, 2.7 and 2.11) as compared to those without (Figures 
2.8-2.10).  Also, mitigators with different terminal modifications (C-, N- and C-, and N-) 
displayed similar CD signals (Figures 2.8-2.10).  
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Figure 2.6 Concentration studies of AAMP-5. CD spectra taken in 50 mM PBS (150mm NaCl); 
pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1. 
 
 
Figure 2.7 Concentration studies of AAMP-6. CD spectra taken in 50 mM PBS (150mm NaCl); 
pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1. 
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Figure 2.8 Concentration studies of AAMP-11.  CD spectra taken in 50 mM PBS (150mm 
NaCl); pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1. 
 
Figure 2.9 Concentration studies of AAMP-16. CD spectra taken in 50 mM PBS (150mm 
NaCl); pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1. 
 
Figure 2.10 Concentration studies of AAMP-19. CD spectra taken in 50 mM PBS (150mm 
NaCl); pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1. 
 
51 
 
 
Figure 2.11 Concentration studies of AAMP-20. CD spectra taken in 50 mM PBS (150mm 
NaCl); pH 7.4. Molar ellipticity- [θ] units- degcm2dmol-1. 
 
2.4 Conclusion 
The various synthetic methods for ααAAs were improved by modifying specific steps. We 
found that ethyl 2-benzyl-2-nitro-3-phenylpropanoate (1b) was unstable to rotary evaporation, 
and the compound was detected in the waste. The focus of future work should be on the 
possibility of using microwave irradiation to hydrolyze the sterically hindered hydantoin. Solid 
phase peptide synthesis of AAMPs without ααAAs was achieved with high purity. Microwave 
technology was successfully used to synthesize AAMPs with ααAAs in higher yields than 
conventional methods.  The CD spectral analysis shows that all AAMPs displayed a 
characteristic random coil structure that was stable to concentration changes. This is important 
for use as mitigators of the Aβ assembly process.  
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CHAPTER 3 
 
STRUCTURE-ACTIVITY RELATIONSHIPS IN PEPTIDE MODULATORS OF 
AMYLOID β-PROTEIN AGGREGATION 
3.1 Introduction 
Alzheimer’s disease is a progressive, neurodegenerative disorder characterized by 
extracellular plaque deposits and neurofibrillary tangles.  The plaque deposits are composed 
primarily of the 39-42 amino acids, natively unfolded amyloid β-peptide (Aβ) that is derived 
from proteolytic cleavage of the extracellular segment of the transmembrane amyloid precursor 
protein (APP).1-3  The normal physiological concentration of Aβ in the brain is less than 10 nM.  
However, the critical concentration for Aβ to aggregate in vitro into amylogenic forms is 1-10 
µM.4, 5  Several hypotheses as to how Aβ aggregates in the brain below the critical concentration 
include concentration of Aβ to several orders of magnitude by membranes or organelles, 
lowering of critical concentration by acidic pH or metal ions, and covalent adducts between Aβ 
and oxidative metabolites allowing Aβ to aggregate at the nanomolar concentrations.5-7   
Conversion of monomeric Aβ peptide into the aggregated products (oligomers, 
protofibrils and fibrils)  in the brain is believed to be the vital event in AD pathology.8, 9  Fibrils 
were previously thought to be the species responsible for neuronal toxicity and cell death 
(amyloid cascade).  However, growing evidence suggests that much smaller soluble oligomeric 
species present in the brain correlates better with severity of AD than plaques (fibrils).2, 10-16  
Therefore assembly of Aβ into either oligomeric or fibrillic assemblies remains a rational target 
to reduce Aβ neurotoxicity.  In addition, fibril dissolution agents could be possible targets for 
reducing plaque loads in the brain. 
 Several approaches aimed at reducing Aβ and its related aggregates in the brain are under 
development.  This include inhibition of proteases involved in the cleavage of Aβ from the 
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amyloid precursor protein (APP),17 antibody therapy through passive immunizations using anti-
Aβ antibodies,18-20 non-antibody based natural mechanism,21-23 small molecules24, and 
peptides.24  Interest in peptide-based aggregation mitigators has intensified because peptides are 
generally more potent, show higher specificity, and fewer toxicology problems than smaller 
organic molecules.  A number of peptide-based AAMPs that alter Aβ aggregation kinetics or 
aggregate morphologies have been developed.  All of these peptide based mitigators exploit the 
self-interacting Aβ central hydrophobic core (Aβ16−20) as a recognition element since the 
assembly of Aβ oligomers is controlled by initial interaction of hydrophobic side-chains. 
 Several modifications on the hydrophobic core (Aβ16−20) aimed at designing AAMPs that 
enhance the disruption of fibril formation and/or induce fibril disassembly have been reported.9, 
25-30
  Murphy and Kessling added an oligolysine tail to the Aβ16-20 hydrophobic core that 
enhanced Aβ aggregation rates resulting in nontoxic fibrillar species.28-30 More recently, RG-/-
RG polar groups added to N- and C- terminal proved to be effective inhibitors of fibril formation 
and protected SH-SY5Y from Aβ toxicity.  Amide backbone modifications of Aβ16-20 core with 
N-methyl amino acids,31, 32 ester linkages,31, 33 and isostructural E-olefin bond34, 35  disrupted 
fibril formation and induced disassembly of preformed fibrils.  Also, Soto and coworkers 
designed the peptide LPFFD containing a single proline residue in the Aβ16-20 core which disrupt 
fibril formation, disassemble preformed fibrils, and increased cell viability.36  Although these 
AAMPs altered the Aβ fibrillization pathway by inducing different Aβ aggregate morphologies, 
the processes often required unusually high inhibitor/Aβ molar ratios.  
Our design of AAMPs is also based on the Aβ16-20 hydrophobic core where some natural 
amino acids were replaced by the modified analogues (ααAAs).  The α-carbon of the natural 
amino acid was modified by introducing a second similar side chain to form ααAAs.  When 
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ααAAs are incorporated in short peptides, they are known to induce stable extended 
conformations which are ideal for interacting with Aβ through hydrogen bonding as well as by 
side-chain interactions.  ααAAs are placed at alternating positions (i, i+2, i+4) which positions 
them on the same hydrogen bonding face of the extended peptide, sterically blocking it from 
further hydrogen bonding hence disrupting fibril propagation.  Also, ααAAs with larger side 
chains impose restrictions of peptides that contain them.  Thus, peptides incorporating ααAAs 
could be better disrupters of β-sheets than proline-containing mitigators.36  Peptide mitigators 
containing ααAAs with methyl side chains have long been known to disrupt β-sheets.37  Thus, 
we hypothesize than mitigators incorporating ααAAs with side chains larger than methyl groups 
should be effective disrupters of β-sheets (disassemble preformed fibrils).  
We previously communicated that peptides containing ααAAs altered Aβ assembly 
pathway at stoichiometric and sub-stoichiometric concentrations resulting in non-fibrillic, non-
toxic assemblies.38   The two mitigators (AMY-1 and AMY-2 with hydrophilic Lys tail on C-and 
N-terminal respectively) mitigated Aβ1-40 fibril formation producing particles with different 
sizes.  Herein, we show that the number and position of ααAAs in the recognition element (Aβ 
central hydrophobic core) of the original mitigator AAMP-138 is important in determining the 
effectiveness of the interaction of the AAMPs with Aβ.  Also, we further examine the role of 
each ααAAs in AAMP-1 through the synthesis of AAMP-1 analogs where ααAAs were 
replaced by their natural amino acid analog (Leu for Dibg, etc). This Aβ1-40-AAMP interaction 
nucleates the size and morphology differences of the nanoparticles formed as determined by 
AFM and TEM.  We also show that AAMPs alone do slowly aggregate forming exclusively 
spherical particles. This might provide insight into the mechanism by which they disrupt Aβ1-40 
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fibril formation. A major finding was  that mitigators, which disrupted fibril formation, also 
disassembled preformed fibrils.  
3.2 Materials and Methods 
3.2.1 Peptide Synthesis  
Samples of AAMPs were prepared from 9H-fluoren-9-ylmethoxycarbonyl (Fmoc) amino acids 
using solid phase peptide synthesis (SPSS) on PAL-PEG-PS resin or Rink amide ChemMatrix 
resin.  Couplings, Fmoc removal, and resin cleavage were carried out using previously described 
methods.39-41  The crude peptides were purified by reversed phase HPLC using a 10% to 70% B 
linear gradient over 60 min [Waters C4 100 Å column using Solvent A (water and 0.1% TFA) 
and solvent B (acetonitrile and 0.1% TFA)].  The purity of the peptides were checked by 
analytical HPLC, and the masses confirmed by ESI-MS.  The percent peptide content was 
established by amino acid analysis. This was discussed in Chapter 2. 
3.2.2 Peptide Monomerization 
Lyophilized Aβ1-40 (Invitrogen Corporation, Carlsbad, CA, USA.) was pretreated to form 
monomeric solutions following our previously published protocol.42  Briefly, Aβ1-40 was 
dissolved in neat trifluoroacetic acid (TFA) at 1 mg/mL and sonicated for 10-20 min.  Removal 
of TFA using a centrivac yielded a dark yellow oil, which was re-dissolved in 1 mL of 
hexafluoroisopropanol (HFIP) at 1 mg/mL and incubated at 37 °C for 1 h.  Removal of HFIP 
yielded a white powder, which was re-dissolved in HFIP and split into 0.25 mg fractions based 
on the assumption that the mass of Aβ1-40 was 50 % at this point in the preparation.  The 
fractions were incubated for 1 h upon which HFIP was removed, and the resulting white powder 
was lyophilized overnight.  The lyophilized white powder was dissolved in 2 mM NaOH and 
PBS (100 mM, 300 mM NaCl, pH 7.4) at 1:1 and centrifuged for 20 min at 13,000 g, which was 
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then ready for the aggregation assay.  The supernatant was subjected to amino acid analysis to 
determine the net peptide content.  
3.2.3 Thioflavin T Aggregation Assays 
Monomerized Aβ
 1-40 was aged alone and in the presence of AAMPs at 37 °C while shaking in 
PBS buffer (50 mM, 150 mM NaCl pH 7.4).  At various time points, 10 µl of sample, 10 µL of 
100µM ThT stock solution in water, and 180 µL of PBS were mixed in a low binding 96 well 
plate with clear bottom (Corning or Falcon).  A ThT fluorescence emission spectrum was 
acquired at 480 nm (excitation at 440 nm) using a fluorescence plate reader (BMG, LABTECH). 
3.2.4 Circular Dichroism 
Monomeric samples of Aβ
 1-40 were aged alone and with equimolar AAMP at 37 °C for several 
days while shaking.  The CD spectrum was recorded at room temperature on an Aviv CD 
spectrometer. 
3.2.5 Atomic Force Microscopy 
 A sample aliquot of 10 µL was diluted two-fold and adsorbed onto the surface of freshly cleaved 
mica (0001) for 5-10 min (Ruby muscovite mica, S&J Trading Co., NY).  The remaining excess 
liquid was absorbed onto a filter paper or lab tissue.  Salts and excess unbound peptide were 
removed by rinsing the surface three times with 40 µL of deionized water.  An Agilent 5500 
atomic force microscope (AFM) equipped with Pico Scan v5.3.3 software was used for surface 
characterizations  (Agilent Technologies AFM, Inc. Chandler, AZ).  Cantilevers (NSL-20) from 
Nanoworld Holdings AG (Schaffhausen, Switzerland) were used for imaging samples by tapping 
mode in air.  The cantilever was driven to oscillate at 185± 10 kHz for ambient AFM 
characterizations.  
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3.2.6 Transmission Electron Microscopy 
Samples for TEM analysis were prepared by placing sample droplet onto a carbon support Cu 
coated grid (EMS 400-CU) for 1-2 min.  Excess sample was absorbed into a filter paper, placed 
onto a droplet of water, and then stained using 2% uranyl acetate droplet.  The grid was cleared 
of excess uranyl acetate, labeled, and then stored in a Petri dish. Images were recorded using a 
JEOL 100 CX TEM, 80 kV accelerating voltage. 
3.3 Results and Discussion 
3.3.1 Design of Amyloid Aggregation Mitigating Peptide 
The central hydrophobic region of Aβ (16-20) is responsible for self-association and aggregation 
leading to the formation of mature fibrils.25  When incorporated into a peptide, ααAAs are 
known to induce extended peptide conformations, which are ideal for interaction with Aβ.43, 44 
We hypothesize that peptides containing alternating natural amino acids and ααAAs in a β-
strand (extended) conformation would have one hydrogen bonding “face” blocked due to the 
steric hindrance associated with ααAAs, and the other face would remain accessible for 
additional β-strand hydrogen bonds.  This design strategy (Figure 1) does not prevent Aβ 
oligomerization but disrupts additional peptides from adding to one face of the growing β-sheet, 
thus changing the Aβ fibrilization pathway.  Previously, we have shown that no fibrils were 
observed from AAMP-1/Aβ1-40 mixture after 4.5 months of incubation at room temperature.38  In 
this study, we seek to elucidate the relationship between size and morphology of the resulting 
assemblies with the side chain functionality, as well as the positioning and distribution of 
ααAAs in the recognition element (KLVFFA) of AAMPs.  A library of  AAMP-1 analogs was 
synthesized and evaluated for ability to disrupt Aβ1-40 fibril formation (Figure 3.1).  Mitigator 
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AAMP-0 (KLVFFK6) previously described by Murphy and coworkers was used as control 
peptide due to the similarity in design strategy to our  AAMPS but with no ααAAs .28, 29  
 
 
Figure 3.1.  Design of mitigators with ααAAs as disrupters of Aβ assembly. 
When bound to amyloid fibrils Thioflavin T dye (ThT) undergoes a red shift of its 
absorbance maximum from 342 to 442 nm, resulting in a characteristic enhanced fluorescence 
signal at 482 nm.  Binding of the ThT dye to Aβ fibrils is complete within 1 min and does not 
interfere with Aβ aggregation.  Thus, ThT fluorescence is commonly used to monitor the 
presence of Aβ fibrils and their rates of formation.  It has also been shown that ThT can bind to 
certain amorphous aggregates to produce an increased fluorescence signal.45-47  Therefore, ThT 
fluorescence cannot be used solely to monitor Aβ formation or disruption.  Other complementary 
methods such as circular dichroism (CD), AFM, and TEM, which reveals the conformation, size, 
length, and morphology of aggregates, are needed to probe mitigation of Aβ1-40  fibril formation 
by designed inhibitors.  We shall emphasize high-resolution AFM data because of its unique 
capability to probe early aggregation products (oligomers) and three-dimensional 
 characterization of Aβ assembly products relative to other microscopy techniques such as TEM. 
48-52
 
Aggregation of Aβ1-40 proceeds via a nucleation
where a nucleus is first formed before growth by A
limiting step, and the presence of seeds greatly accelerates aggregation, possibly bypassing the 
nucleation step.  Thus it is critical
solutions, using a previously published 
3.3.2 Assembly of Aβ1-40 and with the 
3.3.2.1 Effect of AAMPs on Aβ
Figure 3.2.  Disruption of fibril formation by designed AAMPs. Time dependent ThT 
fluorescence of Aβ1−40 assembly in
Fluorescence (ThT) was set arbitrarily to 100 percent relative to A
aged alone. 
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-dependent polymerization mechanism 
β1-40 monomer addition.  This is a rate
 that Aβ1-40  is pretreated to ensure monomeric starting 
protocol.53  
Various AAMPs 
1-40 ThT Fluorescence 
 the presence or absence of the various AAMPs.  
β1-40.  * denotes mitigators 
-
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Monomeric Aβ1-40 was aged alone and in the presence of equimolar AAMPs (40 µM of Aβ1-40 or 
Aβ1-40 /AAMPs) in pH 7.4 phosphate buffer, shaking for 10 min during each h at 37 °C.  The 
time course of ThT fluorescence for Aβ1-40 aged alone or with equimolar mixture of AAMPs is 
presented as a percent of the fluorescence of Aβ1-40 alone (Figure 2).  Mitigators aged alone or in 
the presence of equimolar Aβ1-40 display time dependent increases in ThT fluorescence, 
consistent with increased aggregation although with variable time rates (Figure 2).  Results from 
ThT fluorescence show minimal fluorescence from mitigators aged alone compared to Aβ1-40 or 
AAMP/ Aβ1-40.  These results are indicative of very low aggregation to ThT active species.  In 
some cases, quenching of fluorescent signal was observed after 24 h aging of mitigators alone. 
 A significant observation was the decrease in total ThT fluorescent signal after 3 months 
of incubation in most of the AAMP/Aβ1-40 mixtures.  We can speculate that the decreased 
fluorescence that is observed results from continuous aggregation of these mixtures that leads to 
the formation of larger assemblies, hence precipitating out of solution.  In addition, the decrease 
also can result from mitigator molecules binding and displacing ThT molecules from mature 
fibrils/aggregates.  The control peptide (AAMP-0) described by Murphy and coworkers to 
enhance Aβ1-40 self-assembly forming a network of fibrils 28 was compared to our designed 
mitigators to probe the importance of ααAAs.  A mixture of Aβ1-40/AAMP-0 shows an increase 
in fluorescence of 120% relative to that of Aβ1-40 alone after 3 days of incubation, and an 80 % 
reduction in fluorescence for prolonged aging times.  This is consistent with previous reports 
describing enhanced Aβ1-40 fibrillogenesis.28, 29 
 A significant reduction in Aβ1-40 ThT fluorescence is observed when Aβ1-40 is aged with 
an equimolar mixture of ααAA-AAMPs.  Mitigators AAMP-1, AAMP-2, AAMP-3, AAMP-4, 
AAMP-5, AAMP-7, and AAMP-8 exhibit a reduction of ThT fluorescence between 50 and 80% 
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relative to that of Aβ1-40 alone, even after 3 months of aging.  The only mitigator incorporating 
ααAA that displayed a reduced ThT fluorescence of 20% relative to Aβ1-40 was the 
dipropylglycine (Dpg)-containing AAMP-6, which remained unchanged for even longer 
incubation times (3 months).  Comparison of the sequence of AAMP-6 with other AAMPs that 
showed  reduction in ThT fluorescence between 50-80% relative to the control reveals the 
importance of steric effects and position of ααAAs relative to the recognition element.  
Therefore, fibrillic assemblies were observed in AAMP-6, which incorporates the less bulky 
ααAAs (Dpg) at the C-terminal end of KLVFF recognition core, hence ineffective at blocking 
one hydrogen bonding face from addition of extended peptides.  
3.3.2.2 Effect of ααAA-AAMPs on the Secondary Structure of Aβ1-40 Using Circular 
Dichroism (CD) 
 
To examine the effect of ααAA-AAMPs on Aβ1-40 assemblies, far-UV circular dichroism 
(CD) was employed.  The CD spectra of unstructured monomeric AAMPs and Aβ1-40 showed a 
strong minimum and maximum at around 200 nm and 220 nm respectively, which is consistent 
with a random coil conformation.  After a week of aging AAMPs alone at 37 °C with shaking, 
the random coil conformation observed with monomeric AAMPs remained unchanged with a 
minimum and maximum around 200 and 217 nm respectively, however with weaker intensities 
(Table 3.1).  
 Assembly of Aβ1-40 reveals that the time course of forming β-sheet conformation is 
consistent with previously reported β-sheet rich assemblies.38, 54  The structure of Aβ1-40 alone 
changed from random coil (monomeric) to β-sheet (Figure 3.3) after 7 days of incubation 
(maxima at 198 nm and 214 nm).  In contrast, an equimolar mixture AAMPs and Aβ1-40 leads to 
an unusual CD signature with characteristics of both random coil and β-sheets (Figure 4.3), 
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which is consistent with our previous results of AAMP-1/ Aβ1-40 mixture.38 The Maxima and 
minima of CD signals for Aβ1-40 aged alone and with the various mitigators aged are presented in 
Table 3.1. 
Table 3.1.  Wavelength and corresponding minimum and maximum ellipticities of CD 
analysis of AAMPs alone, Aβ1−40 alone and for AAMP/ Aβ1−40 mixtures. 
entry AAMPs With Aβ (1:1) 
  
3 days aging 7 days aging 
  
λ 
(nm) 
Min/Max 
[θ] × 103 
λ 
(nm) 
Min/Max 
[θ] × 103 
λ 
(nm) 
Min/Max 
[θ] × 103 
λ 
(nm) 
Min/Max 
[θ] × 103 
1 Aβ1−40 206 -4.89 220 -0.275 198 5.03 214 -14.53 
2 AAMP-0 204 -31.34 219 -1.821 195 
(199) 
-14.66 
(-39.86) 
207 
(221) 
2.4 
(3.98) 
3 AAMP-2 202 -20.88 218 21.10 200 
(199) 
-9.89 
-36.271 
218 
(217) 
0.46 
15.823 
4 AAMP-3 202 -50.18 220 -4.12 206 
(195) 
0.297 
-29.63 
220 
(213) 
-3.25 
(15.22) 
5 AAMP-4 204 -18.43 221 2.82 203 
(202) 
-7.93 
(-22.47) 
213 
(215) 
-2.95 
(11.83) 
6 AAMP-6 202 -50.18 218 -4.41 202 
(202) 
-8.27 
(-40.96) 
219 
(219) 
2.35 
(14.12) 
7 AAMP-7 202 -25.34 222 -5.85 200 
202 
-11.20 
(-22.47) 
224 
(221) 
-0.69 
(13.95) 
Note: Values in parenthesis are for AAMPs aged alone after 1 week.    
 
Figure 3.3 Example of CD signature obtained for Aβ1-40 alone, AAMP alone, and Aβ1-40/AAMP 
mixture after 1 week aging. 
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3.3.2.3  Size and Morphology of the Various Structures as Determined Using AFM 
  AAMPs aged alone sparsely aggregate forming spherical beads (Figure 3.4) exclusively with 
mean height range of 4-10 nm (Table 3.2)   
Table 3.2.  Mean heights of spherical aggregates observed after 3 days and 1-week aging 
the various AAMPs alone. 
 
The absence of fibril formation is consistent with CD results, which show little change in the 
random coil conformation with maxima around 220 nm and minima at 217 nm after 1 week of 
incubation.  Also, the minimal ThT fluorescence observed with AAMPs aged alone relative to 
Aβ1-40, suggests that the nanostructures formed are not β-sheet rich.  One possible drawback for 
the observed spherical beads is that they could act as seeds for Aβ1-40 aggregation, increasing the 
rate at which fibrils are formed.  However, fibrils were not observed suggesting that particles 
produced by AAMPs alone do act as seeds for Aβ fibril formation.  We speculate that the 
hydrophobic forces are stronger than hydrogen bonding forces resulting in the observed 
morphology of aggregates formed.  The small-sized spherical aggregates (height ~ 1.6 nm) 
formed when AAMP-1 was aged alone for 3 days may explain the toxicity to the cells we have 
reported before.55  The various nanostructures formed from aging the various AAMPs alone are 
presented in Figure 3.4   
Entry 
 
Mitigators 
 
Type/size of nanostructures formed 
3 days 7 days 90 days 3 days 
aggregate type mean height 
(nm) 
aggregate type mean height 
(nm) 
11 AAMP-0 spherical 4.9±3.4 amorphous 5.4±2.2 
12 AAMP-1 spherical 1.9±1.1 amorphous 9.6±7.7 
13 AAMP-2 spherical 2.1±0.9 amorphous 5.3±4.3 
14 AAMP-3 spherical 2.2±1.5 amorphous 5.3±3.2 
15 AAMP-4 spherical 2.6±3.6 amorphous 6.3±3.6 
16 AAMP-5 spherical 4.3±2.3 amorphous 6.3±3.6 
17 AAMP-6 spherical 3.5±2.1 amorphous 4.6±3.4 
18 AAMP-7 spherical 3.1±1.3 amorphous 5.1±1.9 
19 AAMP-8 spherical 3.2±2.3 amorphous 4.8±2.5 
 Figure 3.4 Spherical aggregates observed 
Topographic AFM views of spherical structures formed by:
height analysis for A; [C] AAMP
for E; [G] AAMP-3; [H] Height distribution histogram for G; [I] AAMP
for I; [K]AAMP-5; [L] Height histogram 
[O]AAMP-7; [P] Height distribution analysis for O;[
for Q;     
AFM was used to characterize A
time intervals as those used for ThT fluorescence assay. 
of aliquots taken at different aging times for A
are shown in Figure 3.5.  Fibrils 
Aβ1-40 alone (Figure 3.5A).  These fibrils had a mean height of 4.2±2.3 nm which is smaller than 
the reported mean height of about 7
by taking multiple cursor measurements of the thickness of the fibrils throughout several 
representative images and is presented in Table 3.3
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after 1 week aging the various AAMPs
- [A] AAMP-0 [B] Corresponding 
-1 [D] Height analysis for C; [E] AAMP-2; [F] Height analysis 
-4; [J] 
for K; [M] AAMP-6; [N] Height analysis for M; 
Q]AAMP-8; [P] Height distribution analysis 
β1-40 or Aβ1-40/AAMP sample aliquots taken at the same 
 Images obtained from AFM 
β1-40, and in presence of AAMP
were the predominant structures observed after 1 week of aging 
-10 nm for mature fibrils.47, 56  The mean height is obtained 
.  
 
 alone.  
Height analysis 
topography 
-0, and AAMP-1 
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Table 3.3.  Comparison for nanostructures observed by AFM for Aβ1-40 alone and with the 
various mitigators. 
 
The distribution of heights is presented as a histogram for each AFM view.  The individual plots 
shown for the surface topography of the various samples are representative views of the 
morphologies observed for multiple areas of the samples.  The presence of smaller sized fibrils is 
an indication that protofibrils and some immature fibrils predominate at the early stage, which is 
supported by height distribution analysis showing fibrils with diameters 2-4 nm accounting for ≥ 
60% of total fibrils (Figure 3.5B).  In contrast, bundles of fibrils (Figure 3.5C) were observed 
after 3 months of incubation as the predominant surface arrangements.  The mean height of the 
fibrils in the clumps was 11.1±6.5 nm and more than 70% of these fibrils had heights ranging 
from 4 to 12 nm (Figure 3.5D) indicating mature fibrils (7-10 nm) had formed. 
The assembly of Aβ1-40 into fibrils is consistent with the proposed hierarchical assembly 
model (HAM model), which predicts that protofilaments predominate at earlier incubation stages 
while protofibrils and fibrils are detected later.  The HAM model also predicts that protofibrils 
entry mitigator type/size of nanostructures formed 
3 days 7 days 90 days 
aggregate 
type 
mean 
height 
(nm) 
aggregate 
type 
mean 
height 
(nm) 
aggregate 
type 
mean 
height 
(nm) 
1 Aβ1-40 proto/fibril 3.44±2.1 fibrils  4.2±2.3 fibrils 11.1±6.5 
2 AAMP-0 protofibrils  8.6±5.7 fibrils  9.1±3.1 - - 
3 AAMP-1 spherical  10.7±5.9 spherical  9.6±7.5 linear 9.5±7.0 
4 AAMP-2 spherical  5.8±3.6 spherical  8.0±4.4 spherical 8.5±3.7 
5 AAMP-3 spherical  1.6±1.4 linear  1.7±1.4 linear 3.7±2.4 
6 AAMP-4 spherical  10.2±4.1 spherical  18.1±8.5 spherical 
rods 
43.22 
7 AAMP-5 spherical  3.8±2.8 spherical  5.0±3.5 spherical 8.0±3.1 
8 AAMP-6 protofibril/ 
linear 
8.0±5.5 rod like 
fibrils  
6.7±2.9 rod like 
fibrils 
8.1±3.2 
9 AAMP-7 spherical  8.6±4.3 spherical  12.7±6.8 spherical 16.0±8.8 
10 AAMP-8 spherical  6.2±2.8 spherical  9.8±5.2 spherical 35.9±15.8 
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and fibrils will exhibit periodicity, variations in height, branching, and clumping at various 
stages of fibrillization.   The unique arrangement of fibrils on the surface observed after 3 
months is consistent with increased β-sheet character of the fibrils.57, 58 
The significance of ααAAs in disrupting fibril formation was evaluated by aging 
equimolar mixtures of Aβ1-40 with AAMP-0 (no ααAAs) and AAMP-1 (with ααAAs).  For 
instance, after 3 days of aging AAMP-0/Aβ1-40 mixture, protofibrils (Figure 3.5E) with mean 
height of 8.6±5.7 nm were the main structures observed.  A dense network of fibrils (Figure 
3.5G) with mean height of 9.1±3.1 nm was observed after 1 week of aging.  The height analysis 
shows a time-dependent increase in fibril heights (Figure 3.5F and 3.5H).  In contrast, mixtures 
of protofibrils and spherical aggregates (Figure 3I) with a mean height of 9.6±7.5 nm were 
observed with AAMP-1 after 1 week of incubation, and rod-like structures (Figure 3.5K) were 
formed after 3 months with a slight increase in mean height as displayed in Figures 3.5J and 3.5I.  
The peptide AAMP-0 (no ααAAs) was used as a control sample to evaluate the effects of 
ααAAs.  This peptide (AAMP-0) was shown previously to enhance the rate of aggregation of
 
Aβ1-40 to form a dense network of fibrils.28 The enhanced Aβ1-40 aggregation rates may also lead 
to thicker fibrils as compared to Aβ1-40 fibrils alone.  The structural design for AAMP-0 and our 
AAMPs are similar except for ααAAs incorporated in the latter (For example Dbg for Phe etc).  
The peptide mitigator AAMP-1 was previously communicated to block Aβ1-40 fibrillization even 
after 4.5 months of incubation at room temperature.38  The different aggregate morphology 
observed from Aβ1-40 aggregation mitigated by AAMP-0 (fibrils) as compared to ααAA-
containing AAMP-1 (mixture of spherical aggregates and rod-like structures) reinforces the 
contrast in using ααAA-containing AAMPs to disrupt fibril formation.  The results for AAMP-1 
with further characterization of the sizes and morphologies of nanostructures formed at different 
 stages of aggregation using high resolution AFM are presented
Although, AAMP-1 was effective at altering A
improved systemic bioavailability the molecular weight of AAMP
as possible.  The AAMP-1 analogs
were used as a control.  
Figure 3.5.  Aggregation of Aβ1-
alone after 1 week of incubation; [B] Height analysis for A; [C] Fibril bundles formed by A
alone after 3 months of incubation; [D] Height analysis for C; [E] Protofibrils formed after 3 
days Aβ1-40  mitigation by AAMP
formed after 1 week Aβ1-40 aggregation mitigation by AAMP
histogram for G; [I] Mixture of spherical and linear aggregates formed after 1 week A
mitigation by AAMP-1; [J] Height analysis for I [K] Spherical and protofibrils observed after 3 
months of Aβ1-40 mitigation by AAMP
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 in Figure 3.5I and 3.5K.  
β1-40 assembly, for optimal use 
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When AAMP-1 analogs with two ααAAs were aged with equimolar Aβ1-40, assemblies 
with different heights and morphologies were formed based on the side chain functionality of the 
ααAAs used.  Spherical aggregates (Figure 3.6A) with mean heights of 8.0 ±4.4 nm and 60% of 
the particles with height range of 4-8 nm (Figure 3.6B) were observed after 1 week of aging Aβ1-
40/AAMP-2 mixture.  The spherical morphology of the aggregates did not change after 3 months 
incubation, but were observed to coalesce forming in some cases aggregate strings (Figure 3.6C).  
The only significant change observed was the slight increase in mean heights (8.5±3.7 nm) as 
shown by height distribution analysis (Figure 3.6D).  Smaller sized spherical aggregates (Figure 
3.6E) with mean height 1.7±1.4 nm were formed from coincubation of Aβ1-40 in the presence of 
equimolar AAMP-3 as compared to AAMP-2.  The same morphology was observed after 3 
months incubation (Figure 3.6G), but with a larger mean height (3.7±2.4 nm) as shown by AFM 
cursor analysis (Figure 3.6F and 3.6H).  Mixtures of spherical aggregates and protofibrils/fibrils 
(visible in the background) with mean height of 18.1±8.5 nm (Figure 3.6I) formed after 1 week 
of Aβ1-40 mitigation by AAMP-4 as compared to mostly spherical particles observed after 3 days 
of incubation.  After 3 months of incubation, the mean height of the spherical aggregates (Figure 
3.6K) more than doubled (43.2±25 nm) with maximum height spanning to 1 µm as shown in 
Figures 3.6J and 3.6L. 
The disruption of fibril formation by AAMPs with two ααAAs is an important finding in 
that these AAMPs portrayed the same or better disruptive properties as the original AAMP-1 
peptide with three ααAAs.  The more interesting aspect of their disruption is the relation 
between size and morphology of the particles formed and the side chain functionality of 
incorporated ααAAs.  Larger particles with similar morphology were formed from Aβ1-40 
aggregation mitigation by AAMP-2 and AAMP-4 as compared to AAMP-3.  The difference in 
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observed heights could be attributed to the side chain functionality of the ααAAs incorporated in 
AAMP-2 (Dbg and Dpg), AAMP-3 (Dibg and Dpg), and AAMP-4 (Dbg and Dibg).  
Surprisingly, Dbg (aromatic)-containing AAMPs (AAMP-2 and AAMP-4) formed larger 
particles as compared to AAMP-3 without Dbg.  Thus incorporation of the additional aromatic 
side-chain in Dbg containing AAMPs may play a role in determining the size and morphology of 
the resultant nanoparticles because aromatic residues are believed to supply energy, order, and 
directionality59, 60 to the Aβ assembly process during fibril formation through aromatic-side 
chain stacking interactions.  
Hydrophobic or steric effects from ααAAs may also lead to the size and morphology of 
structures formed.  For instance, larger spherical aggregates with a few protofibrils/fibrils were 
formed with AAMP-4 as compared to mainly spherical aggregates for AAMP-2.  The different 
sizes and morphology of particles formed can thus be related to the combination of the ααAAs 
used in each AAMP.  They both have aromatic Dbg and a different second ααAAs (Dpg and 
Dibg for AAMP-2 and AAMP-4 respectively).  Thus, steric or hydrophobicity differences 
between Dpg (n-side chains) and Dibg (branched side chains) has influenced the  size and 
morphology of the assemblies formed.   
Positioning of ααAAs relative to each other in the AAMP sequence could influence the 
size and morphology of assemblies formed.  One of the ways to induce extended peptide 
conformations required for the interaction with Aβ in short model peptides is to use ααAAs with 
larger side-chain groups.  For instance, smaller particles were formed by Aβ1-40 mitigation by 
AAMP-3 as compared to either AAMP-2 or AAMP-4.  The two ααAAs are in an i, i+2 
orientation in AAMP-2 and AAMP-4 as compared to an i, i+4 arrangement in AAMP-3.  Other 
examples of i, i+2 design mitigators that were designed by replacement of amide backbone 
 include n-methyl groups, ester linkages, and isostructural E
mitigate fibril formation.31, 32, 34, 61
hydrogen bonding face is crucial for the mitigators to disrupt fibril formatio
arrangement.  In addition, based on our findings with 
elements reported such as N-methylated derivatives and ester linkages
affecting their disruptive properties
Figure 3.6.  Disruption of Aβ1-40 fibril formation by AAMPs with two 
formed after 7 days aging Aβ1-40 in presence of AAMP
[C] After 3 months aging; [D] Corresponding height distribution;
week aging Aβ1-40/AAMP-3 mixture; [F] Height analysis for E; [G] Spherical aggregates after 3 months 
aging; [H] Corresponding height analysis; [I] Mixture of spherical aggregates and protofibrils formed 
after 7 days aging Aβ1-40 in presence of AAMP
After 3 months aging; [L] Matching height distribution histogram.
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  The role of AAMPs with only one ααAAs  on mitigation of Aβ1-40 aggregation was examined 
by aging Aβ1-40 in the presence of equimolar amounts of AAMP-5 (Dibg), AAMP-6 (Dbg), and 
AAMP-7 (Dpg).  Globular particles were observed to form with AAMP-5 (Figure 3.7A) which 
were stable (no fibrils) after 3 months of aging (Figure 3.7C).  Height analysis shows that the 
percentage of the particles with heights ranging from 4-6 nm increased from ~30% for 1 week of 
incubation to over 50% after 3 months of aging (Figure 3.7B and 3.7D).  Co-incubation of Aβ1-
40/AAMP-6 mixture produced protofibrillar structures and rod-like fibrils (Figure 3.7E) after 1 
week.  The protofibrils (Figure 3.7G) observed after 3 months of incubation had increased in 
mean height as displayed by height analysis showing a 2-fold increase  in the percentage of 
particles with heights of 4-6 nm as compared to after 1 week (Figures 3.7F and 3.7H).  Aging of 
Aβ1-40 with equimolar amounts of AAMP-7 resulted in mainly spherical particles after 3 days.  
However, a mixture of spherical aggregates and fibrils/protofibrils (Figure 3.7I) in the 
background were detected after 1-week of incubation with over 50% of the particles with heights 
ranging from 1-10 nm (Figure 3.7J).  After 3 months of aging, the morphology of the particles 
(Figure 3.7K) did not change, but their sizes increased as shown by the increase in the percentage 
of particles with larger heights (Figure 3.7L).  Spherical aggregates (Figure 3.7M) with mean 
heights of 9.8 nm were formed from Aβ1-40 mitigation by AAMP-8 after aging for 1 week.  
Surprisingly, after 3 months, spherical aggregates (Figure 3.7O) observed earlier have grown in 
size to more than a micron in some cases as shown by height analysis (Figure 3.7N and 3.7P)  
Results from Aβ1-40 mitigation by AAMPs with one ααAAs further confirms that side 
chain functionality of incorporated ααAAs influences the size and morphology of the resulting 
nanoparticles.  For example, the different morphology of the particles observed in AAMP-5 as 
compared to AAMP-6 is because of the steric difference between the ααAAs incorporated.  
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Spherical aggregates formed with AAMP-5, which incorporate the more sterically, hindered 
Dibg (isobutyl side chains) as compared to rod-like fibrils in AAMP-6, which contains the less 
sterically hindered Dpg (n-propyl side chains).  In addition, the size and morphology of fibrils 
formed by AAMP-6 were different from those of Aβ1-40 alone.  Fibrils formed by AAMP-6 had 
larger mean heights (6.7 ±2.9 nm) and smaller lengths (≤ 1 micron in length) as compared to 
mature Aβ1-40 fibrils, which were smaller in mean height (4.2±2.3nm) and several microns in 
length. The short fibril lengths suggest lateral interactions of protofilaments rather than the 
intertwining commonly identified during amyloid fibril formation, which can also be because of 
a slower growth rate of protofilaments by elongation and dissociation of monomers.  The 
branching and polymorphic nature of the fibril lengths observed may have been caused by the 
interactions between protofibrils of unequal lengths.58 
Positioning of the ααAAs relative to KLVFF core sequence also influences the 
morphology of the resulting nanoparticles.  The core sequence KLVFF has been shown to be 
critical for the inhibitor peptide to interact with Aβ.  Thus, mitigators with ααAAs placed 
outside this core sequence should have less influence on the interaction with Aβ as compared to 
mitigators with ααAAs incorporated into this region. An example is the different morphology of 
particles formed from Aβ1-40 mitigation by AAMP-8 (nonfibrillic assemblies) with Dpg 
incorporated in the KLVFF core (KLDpgFFAK6) as compared to AAMP-6 (rod-like fibrils) with 
Dpg outside the KLVFF core (KLVFFDpgK6.  We speculate that the AAMPs with ααAAs 
incorporated into the binding motif resulted in increased side-chain to side-chain hydrophobic 
interactions with the homologous core of Aβ.  Thus, blocking one face from interchain hydrogen 
bonding disrupts the Aβ aggregation pathway.     
 Figure 3.7 Topographic AFM images showing disruption of A
with one ααAAs [A]Views of nonfibrillic assemblies formed after 1 week A
mitigation by AAMP-5; [B] Corresponding height distribution; [C] After 3 months; [D] Height 
analysis for C; [E] Progressive AFM Views of rod
Aβ1-40/AAMP-6 mixture; [F] Corresponding height distribution; [G] After 90 days; [H] Height 
distribution analysis for G; [I] Views of spherical and protofibrils/fibrils (background) formed by 
Aβ1-40/AAMP-7 mixture after 1 week aging; [J] Corresponding 
days; [L] Height analysis for K; [M] Views of spherical particles formed by A
mitigation by AAMP-8; [N] Corresponding height distribution; [O] After 3 months; [P] Height 
analysis for O. 
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Interestingly, Aβ1-40 mitigation by AAMP-7 with aromatic Dbg yielded spherical 
aggregates after 3 days of aging.  However, after 1 week of incubation a mixture of spherical 
particles and protofibrils/fibrils in the background with very different morphology relative to Aβ 
fibrils were formed.  This was an unexpected result since it was predicted to disrupt formation of 
fibrillar structures similar to AAMP-5, which incorporates Dibg.  A plausible explanation for the 
different morphology of particles formed by the two mitigators is the aromatic nature of Dbg 
versus Dibg.  This could be due to the enhanced aromatic-stacking interactions asserted by the 
extra aromatic residue.  In summary, after 3 days of incubation, AAMP-4 and AAMP-7 
disrupted fibril formation. However, after 1 week of incubation, a mixture of spherical particles 
and protofibrils/fibrils were observed.  This indicates that higher ratios of AAMP to Aβ1-40 are 
needed to prevent fibril formation.  
3.3.2.4  Morphology of Structures Formed from Aβ1-40 Aggregation Mitigation by the 
Various AAMPs as Observed by TEM 
 
Negatively stained samples of Aβ1-40 alone or mixed with equimolar AAMPs prepared at the 
same time as those of AFM and ThT were examined using TEM to confirm the various 
morphologies observed with AFM.  The morphology of structures (Figure 3.8) formed by Aβ1-40 
alone and with the various AAMPs after 1-week aging was consistent with AFM observations.  
For instance, Aβ1-40 sample showed a typical appearance of amyloid fibrils, shown as a dense 
network of fibrils extending several microns in length.  In contrast, Aβ1-40/AAMP mixtures 
reveal disruption of Aβ1-40 fibrillization yielding particles with different morphologies. 
  Figure 3.8 Morphologies of various particles observed after 1
of  the various AAMPs.  [A] Fibrils formed by A
different view; [C] Fibrils formed by A
mitigation by AAMP-0; [E] Spherical particles
1; [F] Spherical particles were observed from aging A
particles formed from Aβ1-40 aggregation mitigation by AAMP
aggregates and short fibrils were observed from incubating A
Spherical particles formed from 
from Aβ1-40 aggregation mitigation by AAMP
from Aβ1-40 mitigation by AAMP
40/AAMP-8 mixture 
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 3.3.3 Aβ1-40 Fibril Disassembly. 
 
  Several laboratories have reported that a dynamic equilibrium exists between A
monomers/dimers and fibrils.36, 62
plaque deposits commonly present in the brains of patients with AD is to screen for compounds 
that can bind to preformed fibrils, shifting the equilibrium towards prefibrillar species.  Soto 
and Meredith 31, 32 have shown that peptides, which incorporate proline (
methylated amino acids, have the ability to disassemble mature A
of N-methylated peptides and our 
designed to block one hydrogen
Therefore, we hypothesize that 
fibrils because of the more bulky side chains
peptides.   
3.3.3.1 Thioflavin T Fluorescence.
Figure 3.9.  Disassembly of A
disassembly by the various AAMPs after 24 
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To assess the ability of AAMPs to disassemble preformed fibrils, Aβ1-40 was aged for 6 
days at 37 °C while shaking. The mature fibrils that formed were mixed with the various AAMPs 
at 1:1 molar ratio (40 µM final concentration), and incubated while shaking for 24 h.  The extent 
of disassembly was measured by ThT fluorescence.  Results of ThT fluorescence for the 
disassembly of preformed fibrils by the various AAMPs after 24 h incubation are presented in 
Figure 3.9 as %ThT fluorescence relative to that of Aβ1-40 fibrils. 
The general reduction in ThT fluorescence for Aβ1-40 fibril/AAMP mixtures relative to 
that of Aβ1-40 alone indicates fibril disassembly occurred.  For instance, AAMP-1, AAMP-2, 
AAMP-3, and AAMP-4 reduced Aβ ThT fluorescence by nearly 80%.  This is comparable to the 
disassembly of Aβ1-40 fibrils  reported for  β-sheet breaker peptide (LPFFD),36 RGTFEGKF 
peptide,64 and N-methylated peptides,31, 32, 61 although this was at lower AAMP ratios. 
Coincidentally, these same mitigators disrupted Aβ1-40 fibril formation by a similar degree.  
The other AAMPs (AAMP-0 and Dpg-containing AAMP-6) reduced Aβ 1-40 ThT 
fluorescence by ~20%.  The same mitigators only altered fibril morphology when aged with 
monomeric Aβ1-40.  It is possible that ThT Fluorescence could give false positive result for fibril 
disassembly, because reduction in ThT fluorescence can also result from inhibitor molecules 
displacing ThT molecules bound to the preformed fibrils.   
3.3.3.2 Size and Morphology of Structures Formed from Disassembly of Preformed Fibrils 
by Various AAMPs as Determined Using AFM 
 
Results for disassembly of preformed fibrils by AAMPs are summarized in Table 3.3.  
Topographic AFM image of Aβ1-40 taken after six days aging showed a dense network of fibrils 
(Figure 3.10A) with a mean height of 6.2 nm.  The height analysis (Figure 3.10B) reveals the 
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maturity of the fibrils formed, with more than 60% of the fibrils having heights between 4-8 nm, 
consistent with the height of mature fibrils (7-10 nm).   
Table 3.3.  Effect of various AAMPs on Aβ1-40 disassembly. 
 
 Topographic AFM images of Aβ1-40 fibrils disassembled by AAMP-0 (no ααAAs) 
exhibit reduced surface coverage of fibrils and a few spherical particles (Figure 3.10C) consistent 
with the 20% reduction in ThT fluorescence observed relative to that of Aβ1-40.  Also, this is 
consistent with previous reports that AAMP-0 does not induce fibril disassembly.  The height 
distribution shows a distribution similar to that of Aβ1-40 fibrils (Figure 3.10D).  In contrast, 
ααAA-containing AAMPs induced disassembly of preformed fibrils to form nonfibrillic 
assemblies and isolated protofibrils/fibrils.   
entry Mitigators  ααAAs Aggregate type after 24 h 
 dominant 
structures 
mean 
height 
(nm) 
isolated 
structures 
mean 
height 
(nm) 
1 Aβ1-40 - Fibrils 6.2±2.6 - - 
2 AAMP-0 - Fibrils 5.4±2.7 spherical 5.6±2.2 
3 AAMP-1 Dibg, Dbg, Dpg Spherical 5.5±2.9 fibrils 11.2±5.6 
4 AAMP-2 Dbg, Dpg Spherical 3.0±1.2 fibrils 12.4±4.6 
5 AAMP-3 Dibg, Dpg Spherical 7.9±5.0 fibrils 8.4±3.4 
6 AAMP-4 Dbg, Dibg Spherical 11.2±8.2 fibrils 5.2± 2.6 
7 AAMP-5 Dibg Spherical 5.0±4.2 fibrils 5.1±2.1 
8 AAMP-6 Dpg Fibrils 6.6±2.1 spherical 4.7±2.6 
9 AAMP-7 Dbg Spherical 11.3±5.9 fibrillar 5.2±2.5 
10 AAMP-8 Dpg Spherical 10.8±7.5 fibrillar  8.9±4.5 
 Figure 3.10.  Disassembly of A
histogram; [C] Fibrils/protofibrils formed as a result of fibril disassembly by AAMP
Height analysis for C; [E] Spherical aggregates induced by AAMP
Height histogram analysis for E; [G] Spherica
[H] Height analysis for G; [I]  Spherical aggregates from disassembly by AAMP
Corresponding height analysis; [K] Spherical assemblies formed from fibril disassembly by 
AAMP-4; [L] Height histogram for
 
Nonfibrillic assemblies and a few isolated fibrillar structures were the main structures 
observed from Aβ
-40 fibril disassembly by AAMP
same result (nonfibrillic assemblies) was also observed with AAMP
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(Figure 3.10I), and AAMP-4 (Figure 3.10K), incorporating two ααAAs as compared to AAMP-
1.  In addition to observing nonfibrillic assemblies, isolated protofibrils (beaded morphology) 
and fibrils (smooth) were detected in these mixtures.  The height distribution reveals that most of 
the particles formed were less than 10 nm in height (Figure 3.10D, 3.10F, 3.10H, 3.10J, and 
3.10L).  Coincidentally, these same AAMPs showed up to 80% reduction in ThT fluorescence.  
Thus, ααAAs play a role in disassembly of preformed fibrils as seen from fibrils being the 
predominant species formed with AAMP-0 (no ααAAs) as compared to nonfibrillic assemblies 
formed with ααAA-containing AAMPs (for example AAMP-1, AAMP-2 etc).  This is consistent 
with the ThT fluorescence observations.  Significant also, was the increased heights of isolated 
fibrils formed by disassembly of preformed fibrils by ααAA-containing AAMPs as compared to 
either Aβ1-40 fibrils or AAMP-0 (Table 3.3).  This may suggest that ααAAMPs binds to fibrils or 
cause the fibrils to coalesce resulting in increased heights. 
Disassembly by AAMPs with one ααAA resulted in mixtures of spherical particles and 
protofibrils/fibrils.  For instance, spherical particles and isolated fibrils/protofibrils were formed 
from Aβ1-40 fibril disassembly by AAMP-5 (Figure 3.11A), AAMP-7 (Figure 3.11E) and 
AAMP-8 (Figure 3.11G). In contrast, disassembly of performed fibrils by AAMP-6 formed 
mainly fibrillar structures (Figure 3.11C) that exhibited a beaded morphology and a periodicity 
characteristic of protofibrils.  
 The spherical particles observed from disassembly by AAMP-7 and AAMP-8 is larger 
assemblies as compared to AAMP-5, as shown the height analysis (Figure 8B, 8F, and 8H).  
Surprisingly, similar trends were observed for the assembly of Aβ1-40 in the presence of these 
AAMPs.  Thus, aromaticity (AAMP-7) and steric effects (AAMP-8) play a part in the 
disassembly process.  Isolated protofibrils/fibrils observed along with spherical particles for 
 AAMP-7 and AAMP-8, were shorter in length
compared to Aβ1-40 fibrils.  Also, t
with beaded morphology but with similar height distribution (Figur
(Table 3.3) as compared to Aβ
disassembly or fibril breakage of preformed fibrils forming protofibrils (beaded mo
and short fibrils with mean heights 
disassembly of Aβ1-40 preformed fibrils and disruption of fibril formation by AAMP
that positioning of ααAAs relative to KLVFF influences both 
processes. 
 
Figure 3.11. Disassembly of A
AAMP-5 fibril disassembly; [B] Height histogram analysis for A; [C] Fibrils/protofibrils formed 
as a result of fibril disassembly by AAMP
from disassembly by AAMP-7; [F] Corresponding height analysis; [G] Spherical assemblies 
formed from fibril disassembly by AAMP
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 Figure 3.12 Disassembly of Aβ
preformed fibrils zoom in view; 
aggregates and isolated fibrils formed 
formed from disassembly by AAMP
formed from disassembly by AAMP
disassembly by AAMP-3; [H] 
Mixture of spherical aggregates
formed from disassembly by AAMP
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The observed disassembly of preformed fibrils into either oligomeric, or prefibrillar 
particles (precursors of fibril formation) indicates a shift in equilibrium.  It has been shown that 
fibrils elongate by monomer addition to the fibril ends.  Therefore, disassembly of fibrils 
suggests that AAMP possibly binds at the fibril end which shifts the thermodynamic equilibrium 
back towards oligomeric (AAMP-5, AAMP-7 and AAMP-8) and protofibrillar (AAMP-6) 
assemblies.  Even in cases where fibrils/protofibrils were observed, the surface coverage was 
profoundly reduced as compared with the dense network of Aβ1-40 fibrils, suggesting some 
amount of disassembly occurred. 
3.3.3.3 Morphology of Structures Formed from Disassembly of Preformed Fibrils by 
Various AAMPs as Determined Using TEM.   
 
Negatively stained samples of Aβ1-40 pre-formed fibrils or those mixed with various AAMPs 
prepared at the same time as those of AFM and ThT were examined using TEM to confirm the 
various morphologies observed with AFM.  The morphology of Aβ1-40 pre-formed fibrils and 
structures resulting from disassembly by the various AAMPs observed after 24 hr aging (Figure 
3.12)  were consistent with AFM observations.  For instance, Aβ1-40 sample showed a typical 
appearance of amyloid fibrils, shown as a dense network of fibrils extending several microns in 
length.  In contrast, Aβ1-40/AAMP mixtures reveal disassembly of Aβ1-40 fibrils yielding particles 
with different morphologies. 
Our study validates the use of ααAAs as disrupting elements when incorporated into the 
KLVFF motif for designing amyloid aggregation mitigating peptides, as indicated by the absence 
of fibrillic assemblies in comparison to the control peptide (AAMP-0).  We showed that the side 
chain interactions associated with the various ααAAs are important in disrupting fibril 
formation.  A major finding was that the mitigators incorporating one ααAA were as effective in 
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disrupting Aβ1-40 fibril formation as the ones with two or three ααAAs.  Thus, these findings 
support our efforts to reduce the overall molecular weight of the peptide without affecting its 
efficacy for optimal in vivo use and improved systemic bioavailability.  
Interestingly, we found that the mitigators, which disrupted fibril formation, also 
disassembled fibrils.  This suggests the existence of an equilibrium between Aβ1-40 
monomers/dimers and fibrils.  Molecular dynamic simulations have been employed to study the 
mechanism of how these mitigators interact and disassemble fibrils.63, 65, 66  Recently, Yassmine 
et al  showed through simulation the disassembly of Aβ16-22 protofibril by N-methylated 
inhibitors.67  They reported that N-methylated inhibitors interact with the protofibril by both 
lateral and longitudinal association, thereby disrupting the β-sheet extension and its lateral 
association into layers.  More importantly, they showed that the inhibitor peptides intercalate and 
possibly sequester the Aβ peptides, which we believe to be the mode of action for our designed 
ααAA-AAMPs in disrupting Aβ1-40 fibrillogenesis.  This is also true based on Tycko’s structural 
model,68 where we hypothesize that the interaction of ααAA-AAMPs with  Aβ1-40 at the region 
17-20 disrupts the “bend” segment between the two β-strands, affecting β-sheet extension and 
packing during fibril formation.  
 The formation of oligomeric assemblies, as shown in computer simulations and 
experimental data, proceeds via two steps.  The initial step is coalescence driven by the rapid 
formation of nonspecific hydrophobic interactions.  This is followed by a conformational 
conversion to ordered β-sheet structures because of the slow formation of highly directional, 
interchain hydrogen bonds.  Competition between hydrophobic interactions and hydrogen 
bonding is important for determining the morphology of aggregates that formed.  Aging 
conditions can affect hydrogen bonding interactions to yield both fibrillar and non-fibrillar 
87 
 
assemblies with different morphologies but with the same β-sheet content.  Based on our design 
strategy, we hypothesized that AAMPs bind Aβ1-40 and block one face of aggregation, which 
affects the formation of hydrogen bonding interchains and takes Aβ1-40 fibrillogenesis off the 
normal aggregation pathway.  This favors hydrophobic interactions over hydrogen bonding and 
results in nonfibrillic assemblies.  
 One possible application of our findings is that ααAAs can be used to control neuronal 
toxicity from Aβ species.  Neurotoxicity is believed to be a result of aberrant interactions 
between cellular components such as membranes, protasomes and/or molecular chaperons, and 
solvent-exposed hydrophobic surfaces of oligomeric assemblies.  The size of aggregates affects 
these interactions, with the highest toxicity resulting from aggregates with a high surface area to 
volume ratio.  This explains why fibrils and, to some extent, large oligomers are not very toxic 
compared to small oligomeric assemblies.  We showed that position, distribution, and side chain 
functionality of ααAAs incorporated in the binding core affects the size of the resulting 
assemblies.  Thus, we can use ααAAs to influence the desired size of aggregates formed, in 
hopes of controlling neurotoxicity.69-71  Future cytotoxic experiments will be carried out to 
validate this hypothesis.   
3.4 Conclusion 
 Experiments consistently demostrate that mixtures with more than 50% Aβ aggregation 
mostly likely contain fibrillic assemblies. This is an important observation because there are 
some reports that thioflavin-T binding yields ambiguous results. By compairing our ααAAs-
containing mitigators with the control peptide (no ααAAs), we showed the effectiveness of 
ααAAs as disrupting elements. Furthermore, we also showed that mitigators with one ααAAs 
88 
 
were as effective as those with two or three, depending on their position. This is important 
because it helps us achieve our goal of reducing the molecular weight of the initial mitigator 
AAMP-1 but still maintain/enhance its mitigating properties.  
 We have demostrated that AAMP-1, AAMP-2, AAMP-3, AAMP-4, AAMP-5, AAMP-7 
and AAMP-8, which disrupted fibril formation, also disassembled fibrils forming nonfibrillic 
assemblies.  We also showed that AAMP-0 and AAMP-5 not only mitigated Aβ1-40 fibril 
formation yielding fibrils with a different morphology,  but  also disassembled preformed fibrils, 
forming fibrillar assemblies with similar morphologies to those of protofibrils. This is proof that 
there exists an equillibrium between Aβ1-40 monomers/dimers and fibrils.  
Mitigators incubated alone slowly aggregated to yield spherical aggregates which may explain 
the unexpected toxicity observed with AAMP-1.  However, CD spectra showed that after 7 days 
of aging the random coil conformation seen for monomers was unchanged.  This suggests that 
peptides can oligomerize without changes to β-sheet conformation, a property of nearly all 
polypeptides.  If the AAMPs alone aggregated, they are expected to act as seeds and enhance 
abeta aggregation into fibrils.  However, AFM and TEM results suggest a different mechanism. 
We have shown earlier that AAMP-1 disrupt Aβ1-40 aggregation by acting as co-surfactants.  
This has been supported by molecular dynamic simulations using N-methylated amino acids to 
intercalate and sesquester Aβ1-40 peptide.  There are reports that relate the size of nanoparticles 
formed with the maximum toxicity exhibited by particles with high surface area to volume ratios. 
Number, side chain fuctionality, and distribution of ααAA nucleates the size  and morphology of 
Aβ/AAMP products.  This is a major finding because ααAAs may be employed as a means to 
control the size of resulting nanoparticles and possibly neurotoxicity. 
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CHAPTER 4 
EFFECTS OF TERMINAL MODIFICATIONS OF PEPTIDES DERIVED FROM Aβ 
CENTRAL HYDROPHOBIC CORE ON Aβ1-40-PEPTIDE AGGREGATE SIZE AND 
MORPHOLOGY 
4.1 Introduction 
A standing hypothesis associated with Alzheimer’s Disease (AD) is that aggregation of 
monomeric β-amyloid (Aβ) fibrils into neurotoxic misfolded forms is the key event associated 
with the disease pathogenesis.1-3 Recently, extensive investigation of the aggregation pathway 
reveals that oligomeric assemblies and not mature fibrils are responsible for Aβ neurotoxicity.4-8 
Several approaches have been designed to target the Aβ assembly process in an effort to reduce 
toxic species in the brain.  Peptide-based approaches in particular, are increasingly becoming a 
vital constituent of new therapeutics because of their high specificity and low toxicity as 
compared to small organic molecules.9  
Several groups have developed amyloid aggregation mitigating peptides (AAMPs) based 
on designed changes to the Αβ16-20 central hydrophobic core, KLVFF  fragment, which 
Tjenberg10, 11 showed to be critical for Aβ self-assembly and self-recognition.  To the KLVFF 
core, a “disrupter” group is added that solubilizes either inhibitor-Aβ aggregates or blocks 
further addition of β-sheets through hydrogen bonding.  Disrupters that have been added to 
peptides can be classified as N- or C- terminal modifications,12 conformationally constrained 
amino acids,13 peptide backbone modifications,14 or the use of D-amino acids.15  
An example for N- or C- terminal modifications was the addition of oligolysine chains to 
the C-terminus of the KLVFF motif to design peptide KLVFFKKKKKK that was shown to 
enhance the rate of Aβ1-40 aggregation into fibrils and thereby prevent toxicity against PC12 
cells.12, 16 Also, the rate of Aβ assembly into fibrils was shown to depend on the number of lysine 
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groups present in the mitigator.  Several modifications of the peptide backbone for the KLVFF 
binding motif have been reported.  These include replacement of amide hydrogen with methyl 
groups,14, 17 and replacement of the amide bond with either an ester bond18 or isostructural E-
olefin.19 These modifications were designed to block proliferation of hydrogen bonding between 
β-sheets that is necessary for Aβ fibrillization.  Peptides derived from these modifications were 
found to disrupt Aβ1-40 fibril formation and to disassemble pre-formed fibrils.  For instance, N-
methylated peptide Aβ16-22m14 and esterificated Aβ16-20e18 disrupted fibril formation and 
caused the disassembly of pre-formed fibrils.  Also, it was demonstrated that mutations of the 
Phe19-Phe20 amide bond of Aβ1-40 with an E-olefin bond exclusively produced spherical 
aggregates and fibrillization was not detected despite incubation periods of up to 6 weeks.19, 20   
Conformationally constrained peptides have been shown to be effective at disrupting 
Aβ fibril formation through unfavorable steric interactions.  For instance, a β-sheet breaker 
peptide, iAβ5 containing one proline residue was shown to disrupt fibril formation, disassemble 
pre-formed fibrils and protect against neurotoxicity.21 Our approach for this report involves 
replacing the hydrogen atom of the α-carbon of natural amino acid residues in the KLVFF motif 
with an alkyl substituent.  Thus, the conformational freedom of the peptide is restricted and it is 
forced to adopt an extended conformation that is ideal for interaction with Aβ1-40.  Peptides in an 
extended conformation form two faces where one face is available for interaction with Aβ, while 
the other is sterically blocked, limiting β-sheet extensions required for amyloid fibril 
propagation.  
Apart from blocking hydrogen bonding between β-sheets, incorporation of ααAAs 
within the KLVFF motif also increases the overall hydrophobicity of the mitigator peptide and in 
turn strengthens the hydrophobic interactions with Aβ1-40 target.  Polar groups are normally 
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added to the highly hydrophobic ααAAs-containing KLVFF core to increase the overall 
solubility of the peptide.  Also, modification of the α-carbon helps to decrease susceptibility of 
the mitigator to proteolytic degradation, which will ensure effective delivery of the inhibitor to 
the target organ during in vivo studies.  In general, our design for mitigators combines the 
advantages of both C-terminal and α-carbon modification. 
We have previously developed a mitigator peptide (AMY-1) with C-terminal oligolysine 
chain (KDibgVDbgFDpgK6) and a peptide (AMY-2) with an N-terminal oligolysine chain 
(K7KDibgVDbgFDpg).  Both mitigator peptides AMY-1 and AMY-2 disrupted fibril formation 
and formed spherical aggregates of different heights.22 For optimal use in vivo and improved 
systemic bioavailability, the charge and molecular weight of the mitigator should be greatly 
reduced.  Incorporation of one or two ααAAs in the KLVFF binding motif was previously 
shown to be as effective at disrupting Aβ1-40 fibrillization as compared to the original peptide 
(AAMP-1) with three ααAAs.  Herein, effects of forming Aβ fibrils in the presence of (define 
acronym) AAMPs incorporating different polar solubilizing groups (C- or N-terminal) are 
studied, in an effort to evaluate the effectiveness of reducing the overall charge of the mitigator.  
Also, the effects of ααAA-containing AAMPs with fewer polar groups as compared to the 
original mitigator AAMP-1 with six Lys are presented.   
Peptide analogs modified with α-amino isobutyric acid (also called α-methyl alanine) 
have been shown to be more effective at inducing disassembly of Aβ fibrils than either L-proline 
or D-amino acids in short model peptides.23, 24 The restrictions imposed by α-methyl alanine or 
C-α-tetra substituted-amino acid on conformational freedom are more severe than those of 
proline.  Thus, mitigators containing bulky substituent’s (ααAAs) could be more effective at 
inducing β-sheet disassembly than peptides that incorporate proline.  Simulation experiments 
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have shown N-methylated peptide Aβ16-22m interacts with Aβ16-22 blocking β-sheet extension, 
preventing lateral association into layers and more importantly blocking inhibitor intercalation 
for sequestering Aβ peptides.  Our ααAAs are bulkier that either N-methylated or α-methyl 
alanine model peptide derivatives.  Thus, we hypothesize that ααAA-AAMPs could be more 
effective at both disrupting fibril formation as well as inducing disassembly of pre-formed fibrils. 
4.2 Materials and Methods 
All the materials and methodologies used were described in Chapters 2 and 3. 
4.3 Results and Discussion 
 
4.3.1 Design of Peptides for Mitigating Aβ Aggregation 
 Initial work by Tjenberg identified the Aβ central hydrophobic core KLVFF as the key 
scaffold for designing disrupters of Aβ1-40  fibrillization.10, 11 Disrupting elements have been 
strategically placed at various positions within the Aβ hydrophobic core that either solubilizes 
AAMP-Aβ aggregate (Lys or Arg) or blocks one hydrogen boding face inhibiting β-sheet 
extension or propagation as with N-Me amino acid or ester bonds.  Thus, polar groups such as 
Arg, Lys, Glu, and PEG chains were added to increase the solubility of peptides.  Certain 
mitigators incorporating these polar groups have been shown to be effective at disrupting fibril 
formation.16 
Surface Plasmon resonance (SPR) was employed by Murphy and coworkers25 to study 
the binding of variants related to KLVFF on immobilized Aβ10-35 fibrils.11  Variants with 
positively charged residues (KLVFFKn) added to the C-terminus had higher affinities for 
immobilized Aβ10-35 fibrils than the KLVFF control, while negatively charged residues 
(KLVFFEn) also placed on the C-terminus had a significantly lower binding affinity.  In contrast, 
N-terminal addition (KnKLVFF) of positively charged residues resulted in lower affinity. 
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Binding affinity also is affected by additions of polar groups that do not precede the KLVFF 
region in the parent Aβ sequence.  Therefore, amino acids (for example Gly) that are 
conformationally unrestricted can be used as a “spacer” between the KLVFF motif and 
solubilizing residues.  Using Gly as a spacer between the mitigator KLVFF core and Arg 
residues (solubilizing agents) on both the C- and N- terminus, Brian et al designed the peptide 
RGKLVFFGR.26 This peptide was shown to be an effective disrupter of Aβ1-40 fibril formation 
and prevent neurotoxicity towards human neuroblastoma SHSY5Y cells.  
Table 4.1. Modified AAMPs used to probe the assembly and dissolution of Aβ fibrils.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Red color denotes the various polar groups. Blue color denotes ααAAs. 
 
Entry AAMP Sequence 
1 AAMP-11 RGKLVFFGR 
2 AAMP-12 KGKLVFFGK 
3 AAMP-13 EGKLVFFGE 
4 AAMP-14 (MiniPEG)GKLVFFG(MiniPEG) 
5 AAMP-15 RRRGKLVFFGRRR 
6 AAMP-16 KLVFFGR 
7 AAMP-17 KLVFFG(MiniPEG) 
8 AAMP-18 KLVFFGK 
9 AAMP-19 RGKLVFF 
10 AAMP-20 KLVFFDpgGK 
11 AAMP-21 KGKDibgVFFGK 
12 AAMP-22 KDibgVFFDpgGKKK 
13 AAMP-23 KKKGKLVFFDpgGKKK 
14 AAMP-24 KDibgVFFGKKK 
15 AAMP-25 KLVFFFDpgGKKK 
16 Aβ16-22m K(Me)LV(Me)FF(Me)AE 
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  As part of our continuing work to design more effective ααAA-containing AAMPs, we 
employed  similar strategies for placing spacers between the AAMP core KLVFF and the 
solubilizing groups.  We have previously shown that AAMP-1 disrupted Aβ fibril formation.22 In 
vivo studies of AAMP-1 on APP transgenic mice displayed elevated toxicity at higher 
concentrations.27 The toxicity observed could be related to the six cationic lysine’s which also 
affect the delivery of drugs across the hydrophobic brain barrier during in vivo studies.  Thus, 
positively and negatively charged polar amino acids as well as neutral polar groups such as 
MiniPEG was evaluated for effects on the resulting morphology of seed particles and 
protofibrils.  Our goal was to reduce the overall charge of the original peptide (AAMP-1) without 
sacrificing the mitigator ability to disrupt fibril formation and induce disassembly of pre-formed 
fibrils.  
 
Peptide mitigator AAMP-11 previously described by Brian and coworkers was used as a 
control peptide.  First, variants of AAMP-11 were investigated where Arg was replaced with Lys 
(AAMP-12), Glu (AAMP-13), and MiniPEG (AAMP-14) to evaluate effects of polar groups on 
Aβ1-40 aggregation (Table 1. entries 1-4).  Mitigator AAMP-15 allowed us to probe the effect of 
increasing the number of Arg in the chain to three on both the C-and N-terminus on 
Aβ fibrillogenesis (entry 5).  Peptide mitigators (entries 6-8) were designed to evaluate the effect 
of placing polar groups only on the C-terminus.  The effect of placing polar groups on the N-
terminus was evaluated using AAMP-19 with Arg added only to the N-terminus (entry 9).  We 
have previously shown that three ααAAs incorporated in a mitigator sequence was efficient in 
disrupting the process of Αβ fibrillization.  Thus, mitigators (entries 10-15) were designed to 
probe the effect of the reducing both the number of ααAAs as well polar groups for 
Aβ fibrillization.  We hypothesize that addition of a spacer between the ααAA containing 
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KLVFF mitigator core and solubilizing residues, would improve the interaction between the 
AAMP and the Αβ full sequence length.  The N-methylated peptide, Αβ16-22m (entry 16) 
previously described to disrupt fibril formation and disassemble pre-formed fibrils was used as a 
control peptide because it is similarly designed to block one hydrogen face from  β-sheet 
extension and packing. 
4.3.2 Effects of AAMPs on Aβ1-40ThT Fluorescence 
Thioflavin T (ThT) undergoes a characteristic spectral change upon binding to fibrillar species, 
with maximum emission shifting from 445 to 482 nm.28-30 The intensity of ThT fluorescence is 
directly proportional to amyloid fibril formation.  However, it has also been shown that 
fluorescence can result from ThT dye binding to amorphous aggregates.19, 31  Despite this, ThT 
fluorescence is still widely used to monitor the process of Aβ fibrillization.  Prior to investigating 
the effects of AAMPs on Aβ1-40 aggregation, the individual peptides were first tested alone to 
evaluate tendencies to self-aggregate.  The individual AAMP solutions were aged in 80 µM in 
PBS (pH 7.4) for 1 week at 37 ° with periodic agitation.  Under these conditions, all of the 
AAMPs exhibited < 10 % reduced fluorescence (Figure 4.1) relative to that of Aβ1-40, which 
indicates minimal aggregation into amyloid species.   
 When Aβ1-40 was aged with the various AAMPs at 1:1 molar ratios (40 µM final 
concentration) with periodic agitation, a reduction of Aβ1-40 ThT fluorescence was observed 
(Figure 4.2).  This suggest a disruption of the assembly process for solutions of Aβ1-40 alone, to 
form either nonfibrillic or fibrillar assemblies with different sizes, lengths and morphologies 
relative to those of Aβ1-40 alone.  The AAMPs with N- and C-termini modified using various 
polar groups showed a reduction in ThT fluorescence between 40-70% relative to that of Aβ1-40 
after 1-week incubation.  In particular, AAMP-11 with polar Arg was the only AAMP with less 
 than 50% reduced fluorescence.  The similarity in the percentage of reduced ThT fluorescen
indicates that comparable amounts of amyloid were formed.  When using ThT alone one, could 
falsely argue that AAMP-11 is a better disrupter of A
incorporating a polar group on both termini.  
Figure 4.1. Time dependent ThT fluorescence assay of A
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β fibril formation than the other AAMPs 
 
β alone and AAMPs alone.
ce 
 
 
 Figure 4.2. Time dependent ThT fluorescence assay of A
  The addition of a polar Arg group to only the 
exhibit 80% reduced ThT fluorescence.  
(AAMP-17), Lys (AAMP-18) exhibited a 60% reduction of ThT fluorescence after 1 week of 
incubation.  This indicates that the morphology or size of aggregates formed by AAMP
different from those formed by either AAMP
polar residues placed on the C-terminus had an increased reduction in ThT fluorescence as 
compared to the corresponding mitigators with polar groups added to both 
The AAMP-19 with Arg on the N
to 80% when Arg (AAMP-16) was placed on the 
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β/AAMPs. 
C-terminus in AAMP-11 was found to 
Other AAMPs in the series incorporating MiniPEG 
-17 or AAMP-18.  Interestingly, mitigators with 
C- and 
-terminus showed a reduced fluorescence of 40% as compared 
C-terminus.   
  
-16 is 
N-termini.  
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As part of continuing work for optimizing charge and size of , AAMP-20, AAMP-21, 
AAMP-24 and AAMP-25 exhibited reduced fluorescence by less than 40% implying that they 
might have comparable amounts of amyloid or similar morphology.  However, a potent mitigator 
AAMP-22 with two ααAAs and three lysine’s exhibited 80% reduced ThT fluorescence relative 
to that of Aβ1-40.  Based on ThT results only AAMP-11, AAMP-16, AAMP-22 and AAMP-23 
exhibited a higher reduction in ThT fluorescence relative to Aβ than N-methylated peptide, 
mAβ16-22 previously reported to disrupt fibril formation and to disassemble pre-formed fibrils.14  
 As previously described by Austen and coworkers26 AAMP-11 was found to inhibit 
oligomer formation and prevent Aβ1-40 toxicity towards neuroblastoma SH-5Y5Y cells.  They 
reported that an equimolar mixture of Aβ1-40 /AAMP-11 aged for 12 days under quiescent 
conditions showed reduced fluorescence of over 80% relative to that of Aβ1-40.26  For the same 
peptide after 7 days aging, however we report a lower ThT fluorescence of 63% with a condition 
of periodic agitation, as compared to the previously reported result of over 80% reduction.  
Agitation is normally employed to enhance Aβ aggregation so that it can be analyzed on a 
laboratory time scale, although fibrils formed are less stable and more toxic.32, 33   
4.3.3 Effect of Various AAMPs on Aβ1-40 CD Spectra  
The effect of ααAA-AAMPs on Aβ1-40 assembly into β-sheet structure, was examined using far-
UV circular dichroism (CD).  The CD spectra of monomeric AAMPs and Aβ1-40 had a strong 
minimum near 200 nm and maxima near 220 nm, consistent with an unstructured conformation 
commonly referred to as random coil conformation.  After 1-week of aging at 37 C while 
shaking, all the mitigators exhibited minima in their CD spectra around 200 nm, consistent with 
unchanged random coil conformation.  However, the assembly of Aβ1-40 alone after 1-week 
incubation exhibited a CD spectra with minima around 217 nm (Figure 4.3), consistent with 
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formation of β-sheet rich assemblies.22, 34  In contrast, when Aβ1-40 was aged in the presence of 
equimolar AAMPs, an unusual CD signature with characteristics of random coil and beta sheet 
was observed, consistent with our previous results for an AAMP-1/ Aβ1-40 mixture.22  This 
suggests that our AAMPs delay or disrupt Aβ1-40 aggregation into β-sheet rich assemblies.  
 
Figure 4.3. An example of a CD spectra for AAMP-14 alone, Aβ1-40 alone and Aβ1-40/AAMP-14 
equimolar mixture.    
 
4.3.4 Assembly of Aβ1-40 Alone and with the Various AAMPs Analyzed Using AFM 
Samples of AAMPs alone, Aβ1-40 alone, and mixtures of Aβ1-40/AAMPs mixture, which 
were prepared for the same time intervals as those of the ThT fluorescence assay were examined 
using TEM and AFM.  First, samples from mitigator aged alone were examined to determine the 
morphology of the aggregates responsible for the observed ThT fluorescence.  This is important 
because Aβ1-40 has been shown to aggregate via a nucleation dependent polymerization 
process.35, 36 Thus, aggregates formed by AAMPs could act as seeds, rapidly increasing the rate 
of Aβ assembly into fibrils.  Also, AAMP monomer could be added instead to a growing 
protofibril in place of Αβ monomer capping the Aβ fibrillization or altering the normal 
aggregation pathway leading to formation of fibrils with different morphology.  Peptide 
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mitigators were aged in the absence of Aβ1-40 PBS (50 mM at 37 C with periodic agitation) to 
investigate their self-aggregation.  Topographic images of various samples of AAMPs aged for 
1-week displayed sparse distribution of aggregates on the surface (Figure 4.4) with mean heights 
ranging from 2- 8 nm (Table 4.2). 
Table 4.2:  Size and morphologies of assemblies obtained from topographic AFM 
measurements of products observed from aging AAMPs alone at 37°C. 
 
 
The mean heights of aggregates observed after 1 week of aging shows an increase in height 
consistent with aggregation.  When the mean heights of aggregates formed by the various 
AAMPs were compared, no direct correlation was detected between the mean heights of 
aggregates formed and terminal modifications of the peptides. A significant observation was 
larger aggregates formed by AAMPs with longer polar groups such as AAMP-14 and AAMP-18 
as compared to AAMP-11 or AAMP-12. 
Entry AAMPs Type and size of resulting assemblies 
  3 days 1 week 
  Aggregate 
 type 
Size (nm) Aggregate type Size (nm) 
1 AAMP-11 spherical 2.5±2.1 spherical  3.0±2.1 
2 AAMP-12 spherical 2.1±1.2 Spherical 3.1±1.6 
3 AAMP-13 spherical 2.7±2.1 Spherical 5.5±3.4 
4 AAMP-14 spherical 2.8±1.7 Spherical 7.4±4.7 
5 AAMP-15 spherical 3.3±1.9 spherical 5.3±2.3 
6 AAMP-16 spherical 2.3±1.5 spherical 2.8±1.8 
7 AAMP-17 spherical 3.1±1.7 spherical 3.9±2.3 
8 AAMP-18 spherical 2.4±1.5 spherical 7.9±4.2 
9 AAMP-19 spherical 2.8±1.8 spherical 3.1±2.1 
10 AAMP-20 spherical 3.1±2.2 spherical 4.1±2.5 
11 AAMP-21 spherical 3.2±2.0 spherical 3.6±3.5 
12 AAMP-22 spherical 2.5±1.6 spherical 4.4±2.3 
13 AAMP-23 spherical 2.3±1.6 spherical 3.4±2.1 
14 AAMP-24 spherical 1.9±1.4 spherical 4.4±2.1 
15 AAMP-25 spherical 2.9±2.5 spherical 3.1±1.9 
16 Aβ6-22 spherical 3.9±1.6 spherical 6.1±3.8 
 Figure 4.4 Assembly of AAMPs alone at 37°C and periodic agitation. Topographic AFM views 
of spherical structures formed by:
AAMP-12 [D] Height analysis for C; [E] AAMP
[H] Height distribution histogram for G; [I] AAMP
[L] Height histogram for K; [M] AAMP
Height distribution analysis for O;
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- [A] AAMP-11 [B] Corresponding height analysis for A; [C] 
-13; [F] Height analysis for E; [G] AAMP
-15; [J] Height analysis for I; [K]AAMP
-17; [N] Height analysis for M; [O] AAMP
  
 
-14; 
-16; 
-18; [P] 
 Figure 4.5 Assembly of AAMPs alone at 37°C and periodic agitation. Topographic AFM views 
of spherical structures formed by:
AAMP-20 [D] Height analysis for C; [E] AAMP
[H] Height distribution histogram for G; [I] AAMP
[L] Height histogram for K; [M] AAMP
distribution analysis for O;  
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- [A] AAMP-19 [B] Corresponding height analysis for A; [C] 
-21; [F] Height analysis for E; [G] AAMP
-23; [J] Height analysis for I; [K]
-25; [N] Height analysis for M; [O] Aβ6
 
-22; 
AAMP-24; 
-22; [P] Height 
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Spherical aggregates with mean height range between 3-5 nm were observed for all the 
mitigators incorporating ααAAs into its sequence after 1 week of incubation. Surprisingly, 
smaller aggregates were observed from topographic images of AAMPs incorporating ααAAs 
compared to the more hydrophobic N-methylated control peptide.  This suggests that polar 
groups present in ααAA-AAMPs play a role in aggregation.  When the AAMPs solutions were 
aged under quiescent conditions, aggregates were hardly seen indicating that these mitigators are 
stable at room temperature. 
4.3.4.1 Effect of N- and C-Terminal Modifications of AAMPs on Aβ1-40 Fibrillization  
 The Aβ1-40 sample aged alone showed a dense network of amyloid fibrils averaging 5.4 
nm in height and extending several microns in length after 3 days aging (Figure 4.6A).  A 
predominantly dense network of fibrils averaging 6.9 nm in height and spanning several microns 
in length was observed after 1 week of aging (Figure 4.6C).  The fibrils that formed are 
consistent with the Aβ1-40 aggregation process and fits the proposed hierarchical assembly model 
(HAM model).36, 37  The spherical particles observed within a sea of fibrils after 3 days aging are 
consistent with results expected with periodic or continuous sample agitation.38 The height 
analysis (Figures 4.6B and 4.6D) shows that mature fibrils  with diameter ≥7 nm were 
predominant after 1 week of aging, which coincides with the results observed with maximum 
ThT fluorescence.   
 When Aβ1-40 was aged with the equimolar ratio of AAMPs incorporating differently 
charged polar groups to both C- and N-termini, the normal Aβ1-40 aggregation process was 
disrupted to form either fibrils with different morphology (appearance, length) or spherical 
particles.  A network of protofibrils and fibrils (Figure 4.6E) were the major species observed 
after 3 days of aging Aβ1-40 with Arg-containing AAMP-11.   
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Table 4.3. Size and morphology of Aβ1-40/AAMP variants 
 
The morphology of the AAMP-11 structures (Figure 4.6G) observed after 1 week of 
aging for the most part did not change, except for an increase was observed for the mean heights 
as shown by the histogram analysis (Figures 4.6F and 4.6H).  Similarly, fibrils/protofibrils 
(Figure 4.6I) were observed after 3 days of aging Aβ1-40 with equimolar AAMP-12 containing 
another positively charged group (Lys).  After 1 week incubation of AAMP-12 (Figure 4.6K, 
there was increase in both the mean height (Figures 4.6J and 4.6L) and surface coverage of 
fibrils.  Also, when Aβ1-40 was aged with AAMP-13 containing a negatively charged Glu residue, 
protofibrils and fibrils (Figure 4.6M) were observed after 3 days.  Dense networks of beaded 
fibrils or protofibrils (Figure 4.6O) were detected after 1-week incubation with AAMP-13with 
height distribution (Figures 4.6N and 4.6P) showing increase in particles size.  Interestingly, 
Entry AAMPs Type and size of resulting assemblies 
3 days 1 week 
aggregate type mean 
height (nm) 
aggregate type mean 
height (nm) 
1 Aβ1-40 Fibrils  4.5±1.9 Fibrils  6.9±3.7 
2 AAMP-11 Protofibrils/fibrils 4.3±2.0 Protofibrils/fibrils  6.6±3.1 
3 AAMP-12 Protofibrils/ amorphous 5.3±3.1 Rod shaped fibrils 7.4±3.2 
4 AAMP-13 Amorphous  5.5±3.0 Amorphous  7.2±± 
5 AAMP-14 Amorphous  27.8±13.4 Amorphous  40.1±21.2 
6 AAMP-15 Protofibril/linear 4.3±1.9 Protofibril/rod like 
fibrils 
5.6±2.2 
7 AAMP-16 Spherical  20.9±10.1 Amorphous  36.0±15.3 
8 AAMP-17 Amorphous  8.2±3.7 Amorphous  10.0±4.1 
9 AAMP-18 Protofibrils/amorphous 5.5±2.5 Fibrils  7.5±3.2 
10 AAMP-19 Amorphous/protofibrils 5.9±3.3 Linear/fibrils  9.4±3.8 
11 AAMP-20 Protofibrils  7.3±3.1 Amorphous/linear 23.9±12 
12 AAMP-21 Protofibrils  4.8±3.0 Fibrils  7.6±4.7 
13 AAMP-22 Spherical  5.4±2.3 Amorphous  6.1±2.8 
14 AAMP-23 Amorphous/linear 4.4±2.2 Linear/amorphous 10±5.1 
15 AAMP-24 Spherical  8.7±3.6 Amorphous, linear 6.1±2.4 
16 AAMP-25 Amorphous, protofibrils 5.5±3.4 Fibrils  11.5±7.4 
17 Aβ6-22 Amorphous  10.4±4.5 Amorphous  16.1±9.5 
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spherical particles (Figure 4.6Q) were the major structures observed after 3 days aging Aβ1-40 
with AAMP-14 incorporating a neutral MiniPEG group.  No fibrillar species (Figure 4.6S) were 
observed after 1-week incubation, only spherical particle clumps were observed resulting in a 
height as shown by the height histograms (Figures 4.6R and 4.6T).   
Fibrils were observed to form from aging mixtures of Aβ1-40  with AAMP-11 (Figure 
4.6E), which is in disagreement with published results where fibrils were not detected.26  The 
difference in morphology of the particles that formed could be attributed to differences in the 
aging conditions that were employed.  Sample agitation is widely used to expedite amyloid fibril 
formation.  This implies that under quiescent conditions, AAMP-11 disrupts fibril formation; 
however, fibril morphology is altered when aggregation rates are increased by agitation.  A 
mixture of short fibrils with lengths spanning few microns and linear structures with 
protofibrillar morphology were observed with AAMP-12 incorporating positively charged Lys.  
Both AAMP-11 and AAMP-12 alter Aβ1-40 fibrillization pathway forming fibrils that are short in 
length, more branched, and with lower mean height as compared to those of Aβ1-40 fibrils. 
Surprisingly, this is consistent with SPR studies that showed mitigators with Lys and Arg polar 
residues had identical binding affinities for immobilized Aβ10-35.   
However, a dense network of fibrils (Figure 4.6O) with a beaded morphology was 
observed when Aβ1-40 was aged with AAMP-13 containing negatively charged Glu, after 1-week 
incubation.  The dense network of beaded fibrils observed in AAMP-13 as compared to AAMP-
12 and AAMP-11 is also consistent with lower binding affinity for Aβ from mitigators with 
negatively charged polar groups as observed from SPR studies.25 
 Figure 4.6.  Mitigation of Aβ1-40 
and N-terminus, as viewed by AFM topographs. [A] Fibrils formed after 3 days incubation by 
Aβ1-40 alone; [B] Height analysis for A; [C] Fibrils present after 1 week; [D] Height analysis for 
C; [E] Fibrils formed after mitigation for 3 days by AAMP
Fibrils formed after 1 week; [H] Height distribution histogram for G; [I] Mixture of spherical and 
protofibril structures after 3 days mitigation by AAMP
Spherical and short sized fibrils observed after 1 week; [L] Height histogram 
Protofibrils present after 3 days with AAMP
after 1 week; [P] Height distribution analysis 
mitigation for 3 days by AAMP-
observed after 1 week; [T] Height analysis for S.
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aggregation by AAMPs with polar groups added to both the 
-11; [F] Height analysis for E; [G] 
-12; [J] Height analysis for I; [K] 
for K; 
-13; [N] Height analysis for M; [O] Fibrils formed 
for O; [Q] Spherical structures present after 
14; [R] Height distribution for Q; [S] Spherical structures 
 
C- 
[M] 
113 
 
  The lower binding affinities observed from mitigators with negatively charged polar 
groups was postulated  to be from  possible Coulombic interactions between the positively 
charged polar groups in the mitigator and negatively charged residues in Aβ  (E22 and D23).11  In 
contrast, spherical particles with diameters up to nearly 0.2 microns were observed from aging 
Aβ1-40 in the presence of AAMP-14 (Figure 4.6Q) with MiniPEG (neutral) group.  The MiniPeg 
group is a glycol chain and increases the overall hydrophobicity of the peptide.  Thus, in this 
case increased hydrophobicity is more of a factor as compared to Coulombic interaction 
(AAMP-12, AAMP-11) because Aβ assembly is initially controlled by hydrophobic interactions.  
4.3.4.2 Effect of C-Terminal Modifications of AAMPs on Aβ1-40 Fibrillization 
When three Arg residues were added on each terminus as in AAMP-15, fibrils (Figure 
4.7A) with lengths up to 1-2 microns were observed in AFM topographs.  The fibrils (Figure 
4.7C) observed after 1-week incubation had increased height as shown by cursor analysis 
(Figures 4.7B and 4.7D).  Surprisingly, AAMPs with polar groups added to only the C-terminus 
produced particles with a different morphology as compared to those with polar groups added to 
both termini.  For instance, spherical particles (Figure 4.7E) were the major species observed 
from aging Aβ1-40 with AAMP-16 incorporating Arg on the C-terminus.  The height of these 
particles (Figure 4.7G) increased up to 100 nm after 1-week incubation, shown by height 
distributions (Figures 4.7F and 4.7H).  Mixtures of protofibrils and spherical particles (Figure 
4.7I) were observed after 3 days aging Aβ1-40 in the presence of AAMP-17 containing the neutral 
MiniPEG group.  After 1 week of aging, spherical and linear particles (Figure 4.7K) with 
increased heights (Figures 4.7J and 4.7L) were observed from samples imaged after 1 week.   
 Figure 4.7 Disruption of Aβ1-40 fibril formation by AAMPs with polar groups added to the 
N-terminus, characterized by tapping mode AFM.  [A] 
Aβ1-40 in the presence of AAMP-
week; [D] Height analysis for C; [E] Spherical structures detected after 1 week of aging an 
/AAMP-16 mixture; [F] Corresponding height distribution; [G] After 1 week; [H] Height 
distribution analysis for G; [I] Views of spherical and protofibrils formed by 
mixture after 3 days aging; [J] Corresponding height analysis; [K]; After 
analysis for K; [M] Views of spherical particles and protofibrils formed by 
mitigation by AAMP-18 after 3 days aging; [N] Corresponding height distribution; [O] Fibrils 
detected after 1 week; [P] Height analysis for O
observed after 3 days Aβ1-40  mitigation by AAMP
[S] Fibrils were present after 1 week  aging; [T] Height analysis for S.  
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Views of short fibrils after 3 days aging 
15; [B] Corresponding height distribution for A; [C] After 1 
Aβ1
1 week; [L] Height 
Aβ1-40
. [Q] Spherical aggregates and protofibrils 
-19; [R] Height distribution histogram for Q; 
 
C- or 
Aβ1-40  
-40  /AAMP-17 
  aggregation 
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Also, when Aβ1-40 was aged with AAMP-18 containing another positively charged group 
(Lys), spherical particles, and protofibrils (Figure 4.7M) were detected for samples imaged after 
3 days.  Predominantly, fibrils (Figure O) were observed after 1-week incubation of AAMP-18 
exhibiting an increased height distribution as compared to spherical/protofibrils observed after 3 
days of aging (Figure 4.7N and 4.7P).  When Aβ1-40 was aged in the presence of AAMP-19 with 
polar groups added to the N-terminus, a mixture of spherical and fibrillar structures (Figure 
4.7Q) were observed for AFM images acquired of samples after 3 days aging.  Predominantly, 
short fibrils spanning few microns (Figure 4.7S) and even distribution (Figures 4.7R and 4.7T) 
from those of Aβ were observed from samples taken after 1 week aging.    
Contrary to results observed for AAMP-14, increasing the overall hydrophilicity of the 
peptide by addition of more positively charged Arg for AAMP-15 did not necessarily lead to 
increased disruptive properties.  This suggests the importance of the overall hydrophobicity of 
the peptide, which has been shown to be involved in the initial process of Aβ assembly.  
Modification of the C-terminal of AAMPs with positively charged groups as in AAMP-16 and 
AAMP-17 led to disruption of fibrils yielding either non-fibrillar structures or fibrils with 
different morphologies (fibril length, fibril diameter, and fibril entanglement) as compared to 
structure of Aβ alone.  Analogs of KLVF with C-terminal modification with Arg or Lys have 
been shown to have significantly larger binding affinities for Aβ.25  Thus, the slight changes 
observed for the morphology of the particles could be attributed to the differences in the side 
chain functionality of the polar groups, where Arg has a more stable positive charge from 
delocalization as compared to Lys.   
 Figure 4.8.  Disruption of Aβ1-40
Protofibrils and spherical structures observed after 3 days aging 
AAMP-20; [B] Height distribution for A; [C] Spherical structures and fibrils (backg
observed after 1 week; [D] Corresponding height analysis for C; [E] Views of fibrils with some 
spherical structures detected after 1 week of aging A
height distribution [G] After 1 week; [H] Height distributio
structures observed for Aβ1-40  /AAMP
analysis; [K]; spherical and linear aggregates after 1 week; [L] Height analysis for
 
  When the positively charged residue is replaced with a neutral group (MiniPEG), similar 
disruption was observed, and could be attributed to enhancing hydrophobic
interactions between Aβ and AAMP
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  fibril formation by ααAAs-containing AAMPs;  [A]
Aβ1-40  in the presence of 
β1-40/AAMP-21 mixture; [F] Corresponding 
n analysis for G; [I] Spherical 
-22 mixture after 3 days aging; [J] Corresponding height 
-hydrophobic 
-17.  Mitigators with their N- or C-terminus modif
 
 
round) 
 K.  
ied with 
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the same positively charged polar amino acid residue altered Aβ fibrillization forming particles 
with different morphology.  For instance, fibrils were predominantly formed in AAMP-19 as 
compared to spherical particles in AAMP-16 with N- and C-terminal modified with Arg 
respectively. This is also consistent with binding studies that showed AAMPs with Lys y added 
to the N-terminus had 3-fold lower binding affinities as compared to AAMPs with Lys added to 
C-terminus.   
4.3.4.3 Effect of N- or C-Terminal Modifications of AAMPs on Aβ1-40 Fibrillization  
 
Analogs that incorporate ααAAs were also tested to investigate the effects of ααAAs on 
morphology of Aβ -AAMP aggregate.  Spherical aggregates and isolated protofibrils (Figure 
4.8A) were observed with Dpg-containing AAMP-20 after 3 days of aging.  Spherical aggregates 
(Figure 4.8C) had grown to ~100 nm in diameter after 1 week of incubation as discerned from 
height distribution analysis (Figures 4.8B and 4.8D).  Mixtures of spherical aggregates and 
fibrils/protofibrils (Figures 4.8E and 4.8G) were observed from aging Dibg-containing AAMP-
21 after 3 and 7 days incubation.  The height distribution of the particles increased over the same 
time (Figures 4.8F and 4.8H).   
When Aβ1-40 was aged in the presence of AAMP-22 incorporating two ααAAs, spherical 
particles (Figure 4.8I) were observed after 3 days while spherical and linear particles (Figure 
4.8K) observed after 1 week aging.  The diameters and distribution the particles increased at 
longer aging times as shown by height analysis (Figures 4.8J and 4.8L).  AAMP-20 and AAMP-
21 are similar in design with AAMP-18 and AAMP-12 except for ααAA incorporated in their 
core.  Mixtures of spherical aggregates and fibrils were observed with both AAMP-20 and 
AAMP-21 with diameters of spherical spanning up to a 0.1 micron as compared to primarily 
fibrils, although with different morphology as those of Aβ1-40 .   
 Figure 4.9.  Effects of ααAAs-containing AAMPs on 
and spherical structures were observed after 3 days aging A
[B] Height distribution for A; [C] Spherical structures and linear structures observed after 1 
week; [D] Corresponding height analysis; [E] Spherical
aging Aβ1-40  /AAMP-24 mixture; [F] Height distribution analysis for E; [G] Rod
spherical aggregates observed after 1 week; [H] Corresponding histogram analysis; [I] Spherical 
and protofibrillar structures observed after aging A
height analysis; [K]; After 1 week
 
These are good examples that show the effects of incorporating 
sequence.  When the number of Lys were 
AAMP-22,  compared to AAMP
observed.  This is consisted with increased solubility of A
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Aβ1-40  fibril formation; [A]
β1-40 in the presence of AAMP
 structures observed after 1 week of 
β1-40/AAMP-25 for 3 days; [J] Corresponding 
 [L] Height analysis for K. 
ααAAs in a mitigator 
increased to three and another ααAAs introduced as in 
-20 with only one Lys and ααAA, no fibrillar structures were 
β -AAMP aggregate and steric factors , 
 
 Protofibrils 
-23; 
-like fibrils and 
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crucial in our mitigator design.  This is also consistent with 80% reduced fluorescence observed 
relative to that of Aβ1-40.            
    Spherical and linear structures (Figures 4.9A and 4.9C) were observed in AFM 
topographs of samples after three days and 1 week of incubating Aβ1-40 in the presence of 
AAMP-23 incorporating Dpg and three lysine residues added to both termini.  Spherical 
structures (Figure 4.9E) were observed after 3 days of aging a mixture of Αβ1-40 and AAMP-24.  
After 1 week of incubation, spherical aggregates and protofibrils or linear structures (Figure 
4.9G) were the predominant structures.  On the other hand, after 3 days incubation of an Aβ1-
40/AAMP-25 mixture, spherical aggregates and protofibrils (Figure 4.9I) were observed.  After 1 
week of aging, fibrils (Figure 4.9K) were more abundant.  For all the AAMPs, particles that 
formed were observed to increase in height after longer aging ,as shown by height distributions 
(Figures 4.9B, 4.9D, 4.9F, 4.9H, 4.9J, and 4.9L). 
Addition of three lysine residues to both termini as in AAMP-23, disrupted fibril 
assembly to generate linear structures.  Addition of three lysines to both ends probably increased 
the solubility of Aβ -AAMP aggregates, resulting in disruption of fibrillogenesis.  The different 
morphologies of the particles observed with AAMP-24 as compared to AAMP-25 can be 
attributed to the steric difference between the ααAAs.  Mixtures of spherical particles and 
protofibrils were formed with AAMP-24, which containing the Dibg (isobutyl side chains) as 
compared to fibrils in AAMP-25, which contains Dpg (n-propyl side chains).  This highlights the 
important role of polar groups and steric hindrance to the mechanisms for disruption of Aβ 
fibrillization. 
 
 
 
 
  
 
Figure 4.10 EM micrograph of particles observed after 1
various AAMPs.  [A] Fibrils formed by A
view; [C]; Zoom in view of A
mitigation by AAMP-11; [E] isolated fibrils
12; [F] isolated fibrils were observed from aging A
particles and isolated protofibrils observed from aging 
isolated fibrillar structures observed from incubating A
Spherical particles formed from 
particles observed from Aβ1-40 
formed from Aβ1-40 mitigation by AAMP
mixture. 
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-week aging Aβ1-40 in presence of  the 
β1-40 alone; [B] Fibrils formed by Aβ1-
β1-40 fibrils observed in B [D] Fibrils formed 
 formed from aging Aβ1-40  in presence of 
β1-40/AAMP-13 mixture; [G] 
Aβ1-40 in presence of
β1-40 in presence of AAMP
Aβ1-40 aggregation mitigation by AAMP-16
aggregation mitigation by AAMP-17 [K] Fibrillar structures 
-18; [L] Fibrils observed from aging A
 
40 alone different 
from Aβ1-40  
AAMP-
mainly spherical 
 
AAMP-14; [H] 
-15; [I] 
 [J] No fibrillar 
β1-40/AAMP-19 
 4.3.5 Morphology of Structures F
AAMPs as Observed by TEM 
 
Figure 4.11 EM micrograph of particles observed after 1
various AAMPs.  [A] Isolated fibrils observed from aging A
fibrillar structures formed from aging A
structures formed from aging Aβ
formed from Aβ1-40  mitigation by AAMP
fibrils were formed from aging A
from aging Aβ1-40/AAMP-25 mixture.
 
Negatively stained samples of A
the same time as those of AFM and ThT were examined using TEM to confirm the various 
morphologies observed with AFM.  The morphology of structures (Figure 3.8) formed by A
alone and with the various AAMPs after 1
For instance, Aβ1-40 sample showed a typical appearance of amyloid fibrils, shown as a dense 
network of fibrils extending several microns in length.  In contrast, A
reveal disruption of Aβ1-40 fibrillization yielding particles with different
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ormed from Aβ1-40 Aggregation Mitigation by the 
-week aging Aβ1-40 in presence of  the 
β1-40/AAMP-20 mixture
β1-40 in presence of AAMP-21; [C]; non-
1-40 in presence of AAMP-22 [D] Isolated prefibrillar particles 
-23; [E] Mixture of spherical aggregates and isolated 
β1-40  in presence of AAMP-24; [F] network of fibrils observed 
 
β1-40 alone or mixed with equimolar AAMPs prepared at 
-week aging was consistent with AFM observations.  
β1-40/AAMP mixtures 
 morphologies.
Various 
 
; [B] non-
fibrillar 
β1-40 
 
 4.3.6 Aβ1-40 Fibril Disassembly 
It has been shown that the presence of fibrils in the brain nucleates further deposition of 
plaques in AD.39 It was previously stated that a dynamic equilibrium exists between 
monomers/dimers and fibrils.21, 40, 41
attractive source for development of new therapeutics that will reduce or eliminate plaques in the 
brain.  Previously, β−sheet breaker
disassemble pre-formed fibrils. H
on Aβ fibril disassembly.  Mature fibrils, were formed by incubating A
PBS (pH 7.4) while agitating.  Equimolar mixtures of  fibrils of AAMP/A
were aged for 24 h.  The extent to which AAMPs induced fibril disassembly was monitored 
using ThT fluorescence, as well as images acquired with AFM and TEM.  Results of ThT 
fluorescence are shown in Figure 
Figure 4.12.  Fibril disassembly by various AAMPs as monitored by ThT fluorescence, 
presented as percent relative to that of A
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 This makes agents that induce fibril disassembly an 
21
 and N-methylated  peptides14, 40 have been shown to 
erein, we designed protocols to evaluate the effect of AAMPs 
β1-40 for 1 week at 37 C in 
β1-40 and A
4.12 as percentage relative to that of Aβ1-40.   
 
β1-40. 
β1-40 alone 
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The various AAMPs exhibit reduced fluorescence of more than 50 % relative to that of 
Aβ1-40.  The N-methylated control peptide Aβ16-22m, which has been shown to disassemble 
fibrils, displayed 40 % reduced fluorescence.  Based on ThT fluorescence only, the various 
AAMPs tested exhibited reduced fluorescence comparable to the N-methylated control peptide.  
After 24 h, there is no significant difference in ThT fluorescence observed for AAMPs 
incorporating polar groups on the N-and C-terminus (AAMP-11-15), C-terminus (AAMP-16-
18), N-terminus (AAMP-19) or ααAA-containing AAMPs (AAMP-20-25).  It should also be 
noted that the reduced fluorescence exhibited by the various AAMPs does not necessarily 
indicate the absence of fibrils.  This is because inhibitor or disrupter molecules can bind fibrils 
displacing bound ThT molecule resulting in reduced fluorescence. 
4.3.6.1 Size and Morphology of Structures Formed from  Aβ1-40 Disassembly by AAMPs 
Table 4.4.  Effect of various AAMPs on Aβ disassembly 
 
entry AAMPs size and morphology of resulting assemblies 
24 hr 
predominant/isolated structures Size (nm) 
1 Aβ1-40 fibrils 7.9±3.2 
2 AAMP-11 spherical /protofibrils 6.5±4.3 
3 AAMP-12 spherical/fibrils 6.3±3.2 
4 AAMP-13 spherical 15.8±10.6 
5 AAMP-14 protofibrils/amorphous 19.8±11.1 
6 AAMP-15 spherical 7.0±4.0 
7 AAMP-16 fibrils/spherical 7.5±4.6 
8 AAMP-17 spherical/protofibrils 7.2±3.6 
9 AAMP-18 protofibrils/fibrils 11.7±6.7 
10 AAMP-19 fibrils 5.3±3.6 
11 AAMP-20 protofibrils/fibrils 9.6±4.6 
12 AAMP-21 spherical/protofibrils 7.2±3.5 
13 AAMP-22 spherical/linear 11.2±6.5 
14 AAMP-23 spherical 13.4±8.4 
15 AAMP-24 spherical/protofibrils 8.4±3.1 
16 AAMP-25 fibrils 8.0±3.8 
17 Aβ16-22m spherical 35.6±20.4 
 Figure 4.13.  Disassembly of pre
[B] Corresponding height histogram.  
AAMP-11; [D] Histogram analysis for C; [E] Partial disassembly by AAMP
histogram analysis for E; [G] Spherical particles formed by AAMP
Height analysis for G; [I]  Spherical aggregates and fibrils(background) formed from 
disassembly by AAMP-14; [J] Corresponding height analysis; [K] Isolated fibrils present from 
disassembly by AAMP-15; [L] Height histogram for K; [M]  Mixture of short and long fibrils 
observed from disassembly by AAMP
showing beaded sections for Aβ1
histogram; [Q] Fibrils showing nucleation units for
18; [R] Corresponding height analysis; [S] Partial pre
AAMP-19; [T] Height histogram for O.  
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-formed fibrils of Aβ1-40.  [A] Control sample of A
[C] Fibrils and spherical structures after disassembly by 
-12; [F] Height 
-13 fibril disassembly; [H] 
-16; [N] Corresponding height analysis; [O] Fibrils 
-40 fibril disassembly by AAMP-17; [P] Corresponding height 
 mature fibrils after disassembly by
-formed fibril disassembly observed with 
 
 
β1-40 fibrils. 
 AAMP-
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Parallel AFM experiments were conducted for samples prepared at the same time as 
those for ThT fluorescence.  A dense network of fibrils with mean height of 7.9 nm was 
observed from topographic AFM image of Aβ1-40 sample after 1 week of aging (Figure 4.13A).  
Similar observations were found with TEM micrographs, which displayed fibrils spanning 
several microns in length.  Pre-formed fibrils were mixed with the various AAMPs at 1:1 molar 
ratio to evaluate their potential for disassembly. The mean heights and morphologies of the 
various structures formed from topographic AFM data are presented in Table 4. 4.  Fibrils and 
protofibrils were the major structures observed with disassembly of pre-formed fibrils by 
AAMP-11 (Figure 4.13C), AAMP-12 (Figure 4.13E), and AAMP-15 (Figure 4.13K) which all 
have polar groups added to both the C- and N-terminus.   
 Spherical aggregates were the main structures observed after disassembly of pre-formed 
fibrils by AAMP-13 (Figure 4.13G) and AAMP-14 (Figure 4.13I), which incorporate Glu and 
PEG chains respectively into the ,C- and N-terminus.  Predominantly, intact fibrils and isolated 
spherical particles were the major products observed for disassembly of pre-formed fibrils by 
AAMP-16 (Figure 4.13M), AAMP-17 (Figure 4.13O), and AAMP-18 (Figure 4.13Q) with 
different polar groups added only to the C-terminus.  Partially disassembled fibrils were 
observed for AAMP-19 (Figure 4.13S) with polar groups added to N-terminus.  Figures 4.13B, 
4.13D, 4.13F, 4.13H, 4.13J, 4.13L, 4.13N, 4.13P, 4.13R and 4.13T are the corresponding height 
distributions from analysis of multiple cursor profiles.  
The surface coverage and morphology (distribution, appearance, length, etc.) of fibrillar 
structures formed from disassembly by these mitigators indicates partial disassembly took place.  
For instance, fibrillar structures viewed with disassembly by AAMP-15, AAMP-17, and AAMP-
18, showed nucleation units along the fibril length.   
 Figure 4.14.  Disassembly of Aβ
Fibril disassembly by AAMP-20; [B] Co
were observed with disassembly by AAMP
structures with disassembly by  AAMP
beaded morphology observed from disassembly by AAMP
Spherical aggregates and isolated protofibrils formed from disassembly by AAMP
analysis for I; [K] Fibrils and some spherical species observed from fibril disassembly by 
AAMP-25; [L] Corresponding height analysis.
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1-40 pre-formed fibrils imaged using tapping mode AFM.  [A] 
rresponding height histogram.  [C] Spherical structures 
-21; [D] Height analysis for C; [E] Spherical 
-22; [F] Corresponding height histogram; [G] Fibrils with 
-23  [H] Height analysis for 
 
 
G; [I] 
-24; [J] Height 
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This is an indication of immature fibrils or protofibrillar structures, which are precursors 
of mature fibril formation.  In addition, there is evidence of fibril breakage as shown by the 
presence of fibrils with lengths less than a micron (AAMP-16) as compared to those of pre-
formed Aβ1-40 fibrils.  Spherical particles with diameters up to 0.1 micron were formed in the 
presence of AAMP-14.  This underscores the  importance of overall hydrophobicity and the 
length of polar group in the mechanism of disassembly for pre-formed fibrils.  
4.3.6.2 Size and Morphology of Structures Formed from Fibril Disassembly by ααAA-
AAMPs 
 
When ααAA-containing AAMPs were mixed with pre-formed fibrils, the steric nature of ααAAs 
played a role in the disassembly process.  For instance, fibrils/protofibrils (Figure 4.14A) were 
the major species with disassembly by Dpg-containing AAMP-20 as compared to mainly 
spherical particles (Figure 4.14C) observed with Dibg containing AAMP-21.  Similarly, 
spherical particles (Figure 4.14I) and fibrils (Figure 4.14K) were observed for Dibg-containing 
AAMP-24 and Dpg-containing AAMP-25.  When another ααAAs was introduced to AAMP-24 
(Dpg) or AAMP-25 (Dibg) for AAMP-22, spherical particles (Figure 4.14E) with mean height of 
11.2 nm were the major structures of disassembly.  Addition of three Lys to both termini in Dpg-
containing AAMP-23 (Figure 4.14G) evidenced no fibrils in AFM images, suggesting that 
adding polar groups contributes to the disassembly of pre-formed fibrils.  Figures 4.14B, 4.14D, 
4.14F, 4.14H, 4.14J and 4.14L, provide corresponding analysis of the height distribution of 
particles from AFM cursor measurements.  
The distribution of ααAAs in the KLVFF motif is a factor in the disassembly of pre-
formed fibrils.  For instance, fibrillar structures were the major species formed by AAMPs 
incorporating ααAAS outside the KLVFF region as compared to spherical structures observed in 
AAMP-20 or AAMP-25 with ααAAs placed in the KLVFF core.  Increasing the hydrophobicity 
128 
 
or steric hindrance by introducing another ααAA as in AAMP-22, induces disassembly of pre-
formed fibrils to form mainly spherical particles.  Although not conclusive, greater surface 
coverage of disassembled fibrils was observed with AAMP-20 than in the case of AAMP-25 
with one and three C-terminal lysines, respectively.  Also, AAMP-23 with three lysines were 
added to both termini and ααAAs incorporated outside the KLVFF domain, was not expected to 
disassemble fibrils; however intact fibrils were not detected, suggesting that added polar groups 
also contributes to the disassembly of pre-formed fibrils.  This shows that disassembly of pre-
formed fibrils is synergistic combination of the influences of ααAAs as well the number of polar 
groups added.   
4.3.6.3 Morphology of Structures Formed from Aβ1-40 Disassembly by the Various AAMPs 
as Observed by TEM 
 
Negatively stained samples of Aβ1-40 pre-formed fibrils or those mixed with various AAMPs 
prepared at the same time as those of AFM and ThT were examined using TEM to confirm the 
various morphologies observed with AFM.  The morphology of Aβ1-40 pre-formed fibrils and 
structures resulting from disassembly by the various AAMPs observed after 24 hr aging (Figure 
3.12)  were consistent with AFM observations.  For instance, Aβ1-40 sample showed a typical 
appearance of amyloid fibrils, shown as a dense network of fibrils extending several microns in 
length.  In contrast, Aβ1-40/AAMP mixtures reveal disassembly of Aβ1-40 fibrils yielding particles 
with different morphologies. 
 
 
 
 Figure 4.15 Disassembly of Aβ
preformed fibrils different view; 
formed from disassembly by AAMP
isolated fibrils formed from disassembly by AAMP
from disassembly by AAMP-15
fibrillar structures formed from disassembly 
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1-40 preformed fibrils.  [A] Aβ1-40 preformed fibrils; [B]
[C] Fibrils disassembly by AAMP-11; [D]
-12; [E] Fibrils formed from disassembly by AAMP
-14; [G] Non fibrillar structures observed 
; [H]  Fibrils formed from disassembly by AAMP
by AAMP-17. 
 
; Aβ1-40 
 isolated fibrils 
-13;  [F] 
-16; [I] Non 
 Figure 4.16 Disassembly of Aβ1
AAMP-18; [B]; Fibrillar structures observed from disassembly by AAMP
disassembly by AAMP-20; [D] Isolated fibrils 
Spherical aggregates formed from disassembly by AAMP
disassembly by AAMP-23; [G] Isolated fibrils formed from disassembly by AAMP
Fibrils formed from disassembly by AAMP
Aβ16-22m;  
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-40 preformed fibrils.  [A] Fibrils observed from disassembly by 
-19; [C] Fibrils 
formed from disassembly by AAMP
-22;  [F] Isolated fibrils formed 
-25; [I]  Fibrillar structures from disassembly by 
 
-21; [E] 
from 
-24; [H] 
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4.4 Conclusions 
This study demonstrates that terminal modifications of the mitigator core sequence 
(KLVFF) with different polar groups altered Aβ fibrillization yielding particles with different 
morphologies and sizes.  They also disrupt pre-formed fibrils to produce prefibrillar assemblies, 
suggesting that an equilibrium exists between fibrils and prefibrillar aggregates.  Different results 
were obtained with modification of only the C-terminus as compared to changes for both N- and 
C- termini.  In the process, a mitigator AAMP-16 with the C-terminal modified with Arg was 
found to potent disrupter of Aβ1-40 fibril assembly, forming spherical aggregates.  This is 
consistent with the previously reported use of Arg to solubilize inhibitors of Aβ1-4242 and α-
synuclein43 fibrillogenesis, and protects differentiated SHSY-5Y neuroblastoma cells against Aβ 
toxicity.  Also, AAMPs with a MiniPEG group were found to disrupt Aβ1-40 fibril formation.  
This is important because it can be used as a replacement for charged polar groups to improve 
systemic bioavailability of a drug during in vivo studies, and hence reduce toxicity as previously 
shown for Lys-containing AAMP-1.  Smaller-sized spherical particles were observed for 
disruption by AAMP-17 as compared to AAMP-14, with C-terminus or C- and N-terminus 
modified with MiniPEG, respectively.  This indicates that the N-terminal modification enhances 
aggregation to form larger assemblies.  We have previously reported similar results where large 
sizes of particles formed with N-terminal modification of  ααAA-KLVFF compared to C-
terminal modification using  six oligolysine chains.22 The particle size difference is closely 
associated with disruption of the hydrophobic C-terminal group44 which has more impact on 
aggregation than the hydrophilic N-terminal.45  
The different morphologies of particles formed with AAMP-19 (fibrils) and AAMP-16 
(spherical aggregates) are attributable   of the N-terminal and C-terminal, respectively.  Through 
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SPR binding studies,   Murphy and coworkers have shown that AAMPs with positively charged 
polar groups placed on the N-terminus have a  3-fold lower affinity for immobilized Aβ10-35 than 
the ones placed on the C-terminus.25 From SPR and our AFM studies, it can be concluded that 
mitigators with a higher affinity for the target Aβ1-40 are better disrupters of Aβ fibrillization  
Higher binding affinities for AAMPs with polar groups added to the C-terminus as compared to 
N-terminus are due to Coulombic interactions between positively charged polar groups in the 
AAMP (Lys, Arg) and negatively charged residues (E22 and D23) in Aβ.  Coulombic 
interactions can also occur for AAMPs with polar groups added to the N-terminus, but the 
AAMP has to align in an antiparallel manner to align the two appositively charged groups in Aβ 
and AAMP.  Even with antiparallel orientation, SPR studies have demonstrated lower binding 
affinities as compared to the parallel orientation.25  
The AAMPs incorporating ααAAs were better disrupters of Aβ fibrillization as 
compared to AAMPs without ααAAs.  For instance, linear structures and fibrils were formed 
from incubation of Aβ1-40 in the presence of ααAA-containing AAMP-20 and AAMP-18 
respectively.  This is because incorporating ααAAs in the AAMP core forces the peptide to 
adopt an extended conformation that is ideal for interacting with Aβ1-40 through side chain-side 
chain hydrophobic interactions
.
  Also, incorporation of ααAAs into the mitigator core increases 
its hydrophobic character and in essence, impacts Aβ1-40 assembly since the initial aggregation is 
controlled by hydrophobic interactions.  Mitigator AAMP-22 incorporating two ααAAs in the 
KLVFF motif and containing three lysines on the C-terminus was found to have similar 
disruptive properties as compared to AAMP-3 (Chapter 3) with six lysines.22 This shows that the 
number of lysines can be reduced without affecting solubility and disruptive properties of the 
mitigator.  
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Topographic AFM data of the disassembly of pre-formed fibrils show agreement with 
data from ThT fluorescence.  The lower percent ThT fluorescence exhibited by AAMP/ Aβ1-40 
mixtures is consistent with the observations of lower surface coverage of fibrils.  Peptides, which 
have their termini modified with Lys, Arg, Glu and glycol chains have been shown to be 
effective at disrupting fibril formation as well as to protect against neuronal toxicity.14, 18, 26, 46 
Fibrils/protofibrils were observed in AAMPs without ααAAs as with AFM and TEM data.  
Mitigators, AAMP-21, AAMP-22, AAMP-23 induced disassembly of pre-formed fibrils to a 
similar degree to N-methylated peptide, Aβ16-22m which was previously shown to disassemble 
pre-formed fibrils.14 The N-methylated, Aβ16-22m as disassembled pre-formed fibrils, yielded 
large spherical aggregates with mean heights of 35.6 nm.  In contrast, smaller aggregates were 
observed with ααAA-AAMPs.  The difference in the height of assemblies that formed can only 
be attributable to the added polar groups.  Thus, polar groups play a role in determining the size 
of assemblies formed.  We hypothesize that substitution of hydrogen atom on α-carbon of certain 
amino acids in the critical KLVFF region with an alkyl substituent yields a more hydrophobic 
peptide.  Initial assembly of Aβ oligomers is controlled by the hydrophobic side-chains. Thus, 
increasing the hydrophobicity of this region should also enhance interactions between Aβ and 
the mitigator, leading to both disruption of Aβ assembly into fibrils as well as the disassembly of 
pre-formed fibrils.   
 Also, because of terminal modifications with different polar groups, potent mitigators of 
Aβ1-40 fibrillization were found, where the most interesting are the ones with neutral MiniPEG 
polar groups.  Previous designs mostly used positively charged amino acids such as Lys or Arg, 
which makes peptide delivery through the brain barrier difficult.  Thus, this study serves as a 
foundation for future design of more effective peptides with increased systemic bioavailability 
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and for optimal use in vivo.  In addition, there is increasing evidence that an equilibrium exists 
between fibrils and monomers.41, 47, 48  Mitigator KLVFFK6 was previously shown by Murphy 
and coworkers to alter the Aβ1-40 fibrillization process, forming fibrils with different 
morphologies that were protective against Aβ cytotoxicity.  The non-toxic nature of these fibrils 
is believed to be because they  are stable to the equilibrium change unlike Aβ fibrils which are in 
constant equilibrium with the more toxic oligomeric assemblies.12  Thus, future cytotoxicity 
experiments on mitigators that form fibrils with different morphology as those of Aβ1-40 fibrils 
will further provide a basis for design of mitigators that result in fibrils that are stable and protect 
against neurotoxicity.  Also, we designed mitigators that induced partial disassembly of pre-
formed fibrils.  The mechanism of disassembly is believed to occur by mitigator monomers 
binding to the end of fibrils and shifting equilibrium towards prefibrillar assemblies.  Thus, this 
study can guide future designs of dissolution agents.  Lastly, it is possible now to introduce 
unnatural amino acids into a given protein selectively in a cell; therefore, ααAAs would be 
valuable for studying the structural elements responsible for Aβ toxicity in animal models of 
AD. 
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CHAPTER 5 
SUMMARY 
5.1 Discussion 
This dissertation focused on design and synthesis of short model peptides that incorporate 
ααAAs in the core sequence.  ααAAs are known to induce extended peptide conformation (two 
hydrogen bonding face) in a model peptide such that one face is blocked by ααAAs and the 
other is available for interaction with Aβ via side-chain, side-chain hydrophobic interactions.1, 2  
Thus, a series of ααAA-containing AAMPs were designed.   
 Chapter 2 of this dissertation describes the synthesis of ααAAs and incorporation into a 
short model peptides.  Dipropylglycine (Dpg) and Diisobutylglyicine (Dibg) were easily 
synthesized following Fu protocols.3-5 Procedural adjustments especially in the reaction workup 
resulted in increased yields.  Dpg was also synthesized in high yields via palladium catalyzed 
alkylation reaction.  Dibenzylglycine (Dbg) was difficult to synthesize in large amounts such that 
it was enough for peptide synthesis.  The was because the dialkylated ester was unstable to rotary 
evaporation and distilled out with the solvent into the waste flask.  With the increasing success of 
microwave irradiation to hydrolyze sterically hindered hydatoins,6, 7 I hypothesize that Dbg 
hydantoin too can be successfully hydrolyzed using microwave irradiation such that it can easily 
be synthesize in high yields using Bucherer-Bergs method,8 the most common way of 
synthesizing ααAAs. Acylation of N-terminus of ααAAs during peptide synthesis was found to 
be difficult as shown by the very low coupling yields.  Coupling yields were also improved using 
microwave irradiation and a library of AAMPs designed was successfully synthesized. 
Chapter 3 describes solution analysis of the various AAMPs for their ability to disrupt 
properties against Aβ fibrillization.  AAMP-1, which has three ααAAs incorporated in the core 
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sequence, was shown previously to disrupt Aβ fibril formation yielding non-fibrillic assemblies 
that were still stable after 4.5 months.9  In this Chapter, the role of individual ααAAs was 
investigated for their effects on the resulting Aβ-AAMP aggregate size and morphology.  The 
number and position of ααAAs relative to the KLVFF core was shown to be crucial for the 
AAMP to disrupt Aβ fibrillization.  Also, for the first time ααAA-containing AAMPs were 
found to  induce fibril disassembly. These ααAA-AAMPs disassemble fibrils by binding to Aβ 
fibril and because of their bulky side chains, it hinders both β-sheet extension and lateral 
association into layers10 
Chapter 4 describes terminal modifications of AAMPs derived from Aβ central 
hydrophobic core with differently charged polar residues.  Terminal modifications of peptides 
derived from Aβ central hydrophobic core have been shown previously to affect the Aβ-AAMP 
binding affinity or aggregate size and morphology.  For instance  Murphy and Coworkers 
showed that polar groups added to C-terminus have more affinity for immobilized Aβ10-35 than 
polar groups added to the N-terminus.11 Also, Fu et al showed that AMY-2 with six lysines 
added to N-terminus aggregated faster forming large assemblies as compared to AMY-1 with six 
lysine’s added to C-terminus.12, 13  Thus, in this chapter terminal modifications using polar 
residues with different charged led to several potent mitigators of Aβ assembly, majority of 
which incorporate polar groups to the C-terminus.  More importantly, AAMPs incorporating 
miniPEG polar groups were found to be effective against Aβ fibrillization.  It is imperative to 
design mitigators that can  easily be delivered through the brain barrier to their targets.  Thus, 
future design of mitigators should include uncharged polar groups such as miniPEG. Also, the 
number of both Lys and ααAAs  was reduced without changing the ability of the AAMP to 
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disrupt fibril formation.  This is important because our original goal of reducing the charge and 
size of the AAMP was achieved.12, 13  
Currently collaborative work with Dr. Keller at LSU Pennington is ongoing to test the 
assemblies formed from Aβ mitigation by these AAMPs on primary neurons.  
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